<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Pharmacol Pharm Sci</journal-id><journal-id journal-id-type="iso-abbrev">Adv Pharmacol Pharm Sci</journal-id><journal-id journal-id-type="pmc-domain-id">3827</journal-id><journal-id journal-id-type="pmc-domain">advpps</journal-id><journal-id journal-id-type="publisher-id">aps</journal-id><journal-title-group><journal-title>Advances in Pharmacological and Pharmaceutical Sciences</journal-title></journal-title-group><issn pub-type="epub">2633-4690</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11707065</article-id><article-id pub-id-type="pmcid-ver">PMC11707065.1</article-id><article-id pub-id-type="pmcaid">11707065</article-id><article-id pub-id-type="pmcaiid">11707065</article-id><article-id pub-id-type="pmid">39781028</article-id><article-id pub-id-type="doi">10.1155/2024/5248746</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Formulation Design, Optimization, and Evaluation of Solid Lipid Nanoparticles Loaded With an Antiviral Drug Tenofovir Using Box&#8211;Behnken Design for Boosting Oral Bioavailability</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6145-1388</contrib-id><name name-style="western"><surname>M.</surname><given-names initials="SR">Sri Rekha</given-names></name><xref rid="I1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5226-4268</contrib-id><name name-style="western"><surname>S.</surname><given-names initials="S">Sangeetha</given-names></name><email>sangeets2@srmist.edu.in</email><xref rid="I1" ref-type="aff"/></contrib></contrib-group><aff id="I1">Department of Pharmaceutics, SRM College of Pharmacy, SRMIST, Kattankulathur, Chennai, Tamil Nadu, India</aff><author-notes><fn fn-type="other"><p>Academic Editor: Srinivas Mutalik</p></fn></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2024</year></pub-date><volume>2024</volume><issue-id pub-id-type="pmc-issue-id">453536</issue-id><elocation-id>5248746</elocation-id><history><date date-type="received"><day>28</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>08</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-09 11:25:45.297"><day>09</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Sri Rekha M. and Sangeetha S.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="APS2024-5248746.pdf"/><abstract><p>
<bold>Purpose:</bold> The current study aimed to improve the oral bioavailability of tenofovir (TNF), an antihuman immunodeficiency viral (HIV) drug, by integrating it into solid lipid nanoparticles (SLNs), an emerging lipid formulation.</p><p>
<bold>Method:</bold> The suggested SLNs were generated utilizing the microemulsion process, using Compritol 888 ATO. A Box&#8211;Behnken experimental design was attempted to analyze the impact of critical quality attributes (CQAs), such as lipid and surfactant content and homogenization duration on response metrics such as particle size (PS) and percentage entrapment. The prepared SLNs were assessed for entrapment efficiency, zeta potential (ZP), PS, polydispersity index, and in vitro drug release. Moreover, ex vivo permeation tests employing goat intestinal sacs, solid-state characterization by DSC and PXRD, surface morphology by SEM, and in vivo pharmacokinetic evaluation using albino Wistar rats were conducted.</p><p>
<bold>Results:</bold> The research findings demonstrated that a formulation composed of 5.5% lipid and 2% surfactant had a comparatively smaller PS (449.90&#8201;&#177;&#8201;4.79&#8201;nm), a narrow size distribution (0.304&#8201;&#177;&#8201;0.004), and strong stability with an entrapment efficiency of 83.13&#8201;&#177;&#8201;6.34% and a negative ZP (&#8722;18.10&#8201;&#177;&#8201;2.35&#8201;mV). According to in vitro drug release experiments, first-order kinetics were followed and 99% of the medication was released over the time course of 24&#8201;h. In albino Wistar rats, an in vivo pharmacokinetic analysis of the optimized formulation (F10) showed a 12.4-fold improvement in bioavailability over pure TNF solution.</p><p>
<bold>Conclusion:</bold> This study suggests the potential of SLNs in overcoming bioavailability issues, particularly low permeability, gut metabolism, and P-gp efflux transport.</p></abstract><kwd-group kwd-group-type="Inspec"><title>Keywords</title><kwd>Compritol 888 ATO</kwd><kwd>nanocarriers</kwd><kwd>risk assessment</kwd><kwd>solid lipid nanoparticles</kwd><kwd>tenofovir</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Tenofovir (TNF) is a drug used in highly active antiretroviral therapy (HAART), a treatment for human immunodeficiency virus (HIV)/AIDS [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>]. It is a nucleotide reverse transcriptase inhibitor (NtRTI) [<xref rid="B4" ref-type="bibr">4</xref>], and patients in the pediatric and adolescent age range of 12&#8211;18&#8201;years old can use it safely and effectively [<xref rid="B5" ref-type="bibr">5</xref>]. Despite this, its low log <italic toggle="yes">p</italic> value (&#8722;1.6) [<xref rid="B6" ref-type="bibr">6</xref>] and the presence of free hydroxyl groups in its chemical composition, which easily ionize in gut pH and reduce its permeability, limit its oral bioavailability. Furthermore, it is susceptible to metabolism by the gut wall esterases and P-glycoprotein (P-gp) efflux transport system [<xref rid="B7" ref-type="bibr">7</xref>&#8211;<xref rid="B9" ref-type="bibr">9</xref>]. TNF disoproxil fumarate (TDF), a prodrug version, is presently used to increase its bioavailability [<xref rid="B10" ref-type="bibr">10</xref>]. While TDF's pharmacokinetic profile and antiviral activity have been demonstrated to be better than those of its parent drug TNF, its systemic bioavailability is still very low&#8212;it is only 25% bioavailable, according to reports [<xref rid="B11" ref-type="bibr">11</xref>]. Moreover, chronic TDF use has been connected to renal and bone damage [<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>]. TNF reformulation may result in substantial cost savings by lowering the dosage needed while preserving effectiveness, guaranteeing stability across a broad pH range, reducing enzymatic degradation, and preventing P-gp-driven efflux.</p><p>To address the issues mentioned earlier, a new approach is being developed in the form of a colloidal carrier system that can overcome gut metabolism and efflux transport. Among the various options available, solid lipid nanoparticles (SLNs) have garnered considerable interest due to their numerous advantages such as small particle size (PS) [<xref rid="B15" ref-type="bibr">15</xref>], improved drug stability, increased bioavailability [<xref rid="B16" ref-type="bibr">16</xref>], protection against enzymatic metabolism, ability to carry both hydrophilic and lipophilic drugs [<xref rid="B17" ref-type="bibr">17</xref>], ease of large-scale production [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>], and more. SLNs provide the advantages of other colloidal carrier systems while avoiding their drawbacks. Unlike polymeric nanoparticles (NPs), they are biodegradable and biocompatible, and unlike emulsion formulations, they have sustained release effects because the drug is immobilized within solid lipids. Moreover, SLNs have greater chemical and physical stability than liposomes [<xref rid="B20" ref-type="bibr">20</xref>]. Moreover, SLNs circumvent hepatic and enzymatic metabolism and lower P-gp efflux by being absorbed via the lymphatic system [<xref rid="B21" ref-type="bibr">21</xref>]. Therefore, this may be used as an advantage to increase the oral bioavailability of TNF.</p><p>SLNs are submicron colloidal carriers composed of solid lipids that are disseminated in an aqueous surfactant solution. The use of a solid lipid instead of a liquid lipid is an advantage as it has better control over the drug release and can also protect the encapsulated drug from chemical degradation and enzymatic metabolism. Solid lipids, which are part of the biological system and generally recognized as safe (GRAS), such as fatty acids like stearic acid (SA), triglycerides like tristearin and tripalmitin, hard fats like Witepsol, waxes like cetyl palmitate (CP) and beeswax, and acylglycerols like glyceryl monostearate (GMS), are major components of SLN formulations [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. Different technologies used to fabricate SLNs are high-shear homogenization, high-pressure homogenization (HPH) (cold and hot homogenization), solvent emulsification, solvent evaporation, ultrasound, and microemulsion methods [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>].</p><p>TNF is a hydrophilic drug having high solubility (13.4&#8201;mg/mL) and low permeability (log P of &#8722;1.6) [<xref rid="B26" ref-type="bibr">26</xref>], classified as Class III in the Biopharmaceutical Classification System (BCS) [<xref rid="B27" ref-type="bibr">27</xref>]. Its limited permeability is known to cause low oral bioavailability. Although scientists have produced prodrugs [<xref rid="B28" ref-type="bibr">28</xref>] and polymeric NPs [<xref rid="B29" ref-type="bibr">29</xref>] to boost oral bioavailability, none have proposed employing SLNs. However, because hydrophilic medicines often partition in the aqueous phase during manufacture, developing SLNs that can efficiently encapsulate these medications is difficult [<xref rid="B24" ref-type="bibr">24</xref>]. By carefully choosing the appropriate lipids, surfactants, and their composition, this can be avoided. Moreover, examining the effects of different formulations and process factors on the desired attributes of the lipid nanocarriers is crucial to achieving the optimal SLN formulation.</p><p>This study's main objective was to create and enhance TNF-loaded SLNs in order to increase their oral bioavailability using the design of experiments (DOE) process. In order to do this, the formulation was optimized using a Box&#8211;Behnken design (BBD), and the impact of various processing and formulation parameters on crucial quality measures including PS and percentage entrapment efficiency (%EE) of the SLN was investigated. A number of characterization studies were conducted to ascertain the SLNs' shape, size, %EE, and drug release kinetics. Moreover, studies on the excised gut sac and in vivo pharmacokinetics were carried out to enhance the comprehension of the process of oral absorption of SLNs loaded with TNF.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Materials</title><p>A complimentary sample of TNF and Compritol 888 ATO was received from MSN Laboratories Pvt. Ltd., Hyderabad, India. Sigma-Aldrich in Mumbai, India, supplied SA, GMS, cholesterol, poloxamer 188, poloxamer 407, and soya lecithin. Span 60, Tween 80, beeswax, and stearyl alcohol were purchased from Loba Chemie Pvt Ltd. in Mumbai, India. Merck Ltd., Mumbai, India, was the source of HPLC quality solvents such as methanol, acetonitrile, and water. The remaining chemicals and solvents were all of analytical grade.</p></sec><sec id="sec2.2"><title>2.2. Methods</title><sec id="sec2.2.1"><title>2.2.1. Lipid Phase Screening</title><p>While selecting lipids, the maximum solubility of a medication was taken into account. TNF solubility was assessed in a range of lipids, including SA, beeswax, glyceryl palmitostearate (GPS), cholesterol, stearyl alcohol, and GMS. To test for solubility, 1&#8201;g of melted fat that had been heated to 10 degrees Celsius over its melting point was combined with 5&#8201;mg of carefully weighed TNF. Then, a fraction of the medication (5&#8201;mg) was introduced immediately when the previous fraction was dissolved incrementally while being continually swirled at 100&#8201;rpm using an orbital shaking incubator until the drug was no longer able to dissolve in the molten lipids. Following a 24-h shaking period, the solubility was evaluated visually; the appearance of a turbid solution served as the endpoint, and the maximum amount of TNF dissolved in the lipid was recorded. The lipid with the highest drug solubility was chosen for additional formulation research because it was thought to have the highest drug loading capacity [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>].</p></sec><sec id="sec2.2.2"><title>2.2.2. Surfactant Screening</title><p>The average diameter of the particles and the %EE of the resulting SLN dispersion by the surfactant system were used to determine which surfactant to use. Trial batches of SLNs were prepared using a variety of surfactants, such as Span 60, Tween 80, poloxamer 407, and poloxamer 188, in order to determine the best surfactant system. In a nutshell, 3% lipid (Compritol 888 ATO) was taken and melted at 70&#176;C. Similarly, an aqueous phase was produced by dissolving 2% surfactant in the required volume of distilled water at the same temperature. Both phases were mixed and agitated at 500&#8201;rpm for 10 to 15 minutes in order to create a uniform emulsion. Following a high-speed homogenizer run at 20,000&#8201;rpm for 10&#8201;min, the resultant emulsion was assessed for PS and %EE. The highest entrapment and smallest particle diameter were the criteria used to select the surfactant of choice for further experiments [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>].</p></sec><sec id="sec2.2.3"><title>2.2.3. Selection of Formulation Technique</title><p>HPH, high-speed homogenization, ultrasound, solvent emulsification and evaporation, microemulsion technology, and other methods are used in the formulation of SLN. In the current investigation, SLN with a chosen lipid (3% Compritol 888 ATO) and surfactant (1% poloxamer 188) were prepared using widely used procedures such as high-speed homogenization, solvent emulsification and evaporation, and microemulsion techniques. The evaluation of PS and % EE with the trial batches was the basis for choosing the formulation procedure [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>].</p></sec><sec id="sec2.2.4"><title>2.2.4. Drug and Excipient Compatibility Study</title><p>Compatibility tests were conducted using Fourier transform infrared spectroscopy (FTIR) to determine the drug's interaction with certain excipients. The drug, lipid, surfactant, and physical blend of drug and chosen excipients were held at 25&#176;C, 60%&#8201;&#177;&#8201;5%RH for 7&#8201;days. The infrared spectra of these samples were acquired in the 4000&#8201;&#8722;&#8201;400&#8201;cm<sup>&#8722;1</sup> region, and they were compared to look for any notable changes [<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>].</p></sec><sec id="sec2.2.5"><title>2.2.5. Quality by Design and Risk Assessment</title><p>Critical process parameter (CPP) optimization was performed using the quality by design concept. The purpose of the Ishikawa/fishbone diagram for risk assessment is to pinpoint probable sources of product variability [<xref rid="B39" ref-type="bibr">39</xref>]. <xref rid="tab1" ref-type="table"> Table 1</xref> presents several facets of the quality target product profiles (QTPPs) and critical quality attributes (CQAs), whereas <xref rid="fig1" ref-type="fig">Figure 1</xref> illustrates the risk assessment for TNF-loaded SLN development using a fishbone layout.</p></sec><sec id="sec2.2.6"><title>2.2.6. Experimental Design</title><p>Top-notch Box&#8211;Behnken Design (BBD) using Design-Expert software (STAT-EASE 360 trial edition), an optimization strategy comprising three variables and three levels with 13 experimental runs was attempted. To investigate the impact of lipid concentration (A), surfactant concentration (B), and homogenization time (C) on two responses, PS, and %EE, as well as their interaction, the variables were set at low, medium, and high levels. The current study's objective function was chosen to maximize EE while lowering PS. Analysis of variance (ANOVA) was used to assess the statistical reliability of the polynomial equations generated by Design-Expert software. The factor coding and experimental runs are shown in <xref rid="tab2" ref-type="table">Table 2</xref>. Lipid levels were 1%, 5.5%, and 10% at low, medium, and high levels, respectively. Surfactant levels were 1%, 2%, and 3%, while homogenization times were 30, 60, and 90&#8201;min [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>].</p></sec><sec id="sec2.2.7"><title>2.2.7. Method of Preparation</title><p>Using the previously published microemulsion techniques [<xref rid="B41" ref-type="bibr">41</xref>&#8211;<xref rid="B44" ref-type="bibr">44</xref>], TNF-loaded SLNs were prepared using the selected lipid Compritol 888 ATO, the surfactant poloxamer 188, and soy lecithin as cosurfactants. Using the BBD, a total of 13 formulations were created by altering the quantities of lipid, surfactant, and homogenization time, as shown in <xref rid="tab2" ref-type="table">Table 2</xref>. In summary, before adding TNF, the lipid phase (Compritol 888 ATO) was heated by 10&#176;C over its melting point (70&#176;C). The aqueous phase containing the cosurfactant (soya lecithin) and surfactant (poloxamer 188) was heated to the same temperature as the lipid phase. An o/w emulsion was produced by introducing the hot aqueous phase to the molten lipid phase and continuously swirling for 10&#8211;15&#8201;min at 500&#8201;rpm on a magnetic stirrer. Now, the hot emulsion was carefully poured into a beaker containing ice-cold water (8&#176;C) in a dropwise manner under continuous homogenization for the duration given by BBD at 20,000 rpm and then subjected to probe sonication. After 10 minutes of probing sonication at 60% amplitude (Sonics Vibra&#8482; Cell Ultrasonic Processor, 130&#8201;W, 20&#8201;kHz, USA), the generated SLNs with reduced particles to nanoscale were kept at 4&#176;C for further analysis. After 10 minutes of probing sonication at 60% amplitude (Sonics Vibra&#8482; Cell Ultrasonic Processor, 130&#8201;W, 20&#8201;kHz, USA), the generated SLNs with reduced particles to nanoscale were kept at 4&#176;C for further analysis.</p></sec></sec><sec id="sec2.3"><title>2.3. Characterization of Formulated TNF-Loaded SLNs</title><sec id="sec2.3.1"><title>2.3.1. PS, Polydispersity Index (PDI), and Zeta Potential (ZP)</title><p>The Nanoparticle Size Analyzer SZ-100Z, Horiba Ltd., Japan, was used to measure the average diameter of particles, PDI, and ZP of TNF-loaded SLNs. All formulations were diluted to an appropriate concentration with double distilled water prior to testing. The samples were analyzed by placing them in disposable cuvettes, and the findings for PS, PDI, and ZP were noted [<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>].</p></sec><sec id="sec2.3.2"><title>2.3.2. EE</title><p>The %EE of TNF-loaded SLNs was measured by an indirect method using a high-speed cooling centrifuge (Remi Instruments, Ltd., Mumbai, India) to assess unentrapped drugs in an aqueous medium. By deducting the amount of drug found in the supernatant from the total amount of drug used to make SLNs, the amount of drug entrapped in SLN was calculated. To put it briefly, a centrifuge tube containing a known volume of TNF-loaded SLN dispersion was centrifuged for 20&#8201;min at 4&#176; C at 12,000&#8201;rpm. After appropriate dilutions, the supernatant was collected and tested for free drug content using a UV&#8211;visible spectrophotometer at 262&#8201;nm (<italic toggle="yes">&#955;</italic><sub>max</sub>) [<xref rid="B44" ref-type="bibr">44</xref>]. The following formula is used to determine the %EE:<disp-formula id="EEq1"><label>(1)</label><mml:math id="M1" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mo>%</mml:mo><mml:mtext>&#8201;entrapment&#8201;efficiency</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>total&#8201;drug&#8201;content</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mtext>free&#8201;drug</mml:mtext></mml:mrow><mml:mrow><mml:mtext>total&#8201;drug&#8201;content</mml:mtext></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p></sec></sec><sec id="sec2.4"><title>2.4. Optimization of Variables</title><p>Based on two quality parameters&#8212;PS and EE, the formulations made in accordance with the experimental design were examined and refined to determine the ideal ratios of lipid, surfactant, and homogenization duration. The trial version of STAT-EASE 360 was used to analyze statistical data using ANOVA, generate model equations, and produce contour plots for every response. The relationship between the independent and dependent variables was also established using three-dimensional (3D) surface plots. The desirability function of PS was set to minimal, and EE was adjusted to greatest in order to optimize the formulation. The optimal formulation was determined by the <italic toggle="yes">p</italic> value, and its validity was confirmed by the predicted <italic toggle="yes">R</italic><sup>2</sup> and ANOVA values [<xref rid="B47" ref-type="bibr">47</xref>].</p></sec><sec id="sec2.5"><title>2.5. In Vitro Drug Release Studies</title><p>In vitro release of TNF from SLN formulation was performed by dialysis membrane diffusion technique [<xref rid="B48" ref-type="bibr">48</xref>&#8211;<xref rid="B50" ref-type="bibr">50</xref>] using a dialysis membrane with a 12,000&#8211;14,000&#8201;Da molecular limit. In summary, the dialysis membrane was knotted at both ends and stretched over the diffusion glass vial after being immersed in the release media for the entire night. A defined volume of TNF-loaded SLN dispersion equivalent to 10&#8201;mg drug was placed in a dialysis tube and then inserted into a beaker containing 100&#8201;mL of diffusion medium. The mixture was held at 37&#8201;&#177;&#8201;0.5&#176;C and swirled continuously at 100&#8201;rpm using a magnetic stirrer (REMI 2MLH). The dissolution analysis was conducted under two distinct conditions: initially, in simulated stomach fluid (pH 1.2) and then in simulated intestinal fluid (pH 6.8) during the final 22 hours. To keep the sink conditions, 2&#8201;mL of aliquots were taken out and replaced with fresh buffer at different time intervals of 0, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21, and 24&#8201;h. A UV&#8211;visible spectrophotometer was used to evaluate each sample at 262&#8201;nm [<xref rid="B51" ref-type="bibr">51</xref>]. The amount of drug released was then used to calculate the cumulative percentage of drug release:<disp-formula id="EEq2"><label>(2)</label><mml:math id="M2" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mtext>amount&#8201;release</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>test&#8201;absorbance</mml:mtext><mml:mo>&#215;</mml:mo><mml:mtext>dilution&#8201;factor</mml:mtext><mml:mo>&#215;</mml:mo><mml:mtext>vol</mml:mtext><mml:mo>.</mml:mo><mml:mtext>&#8201;of&#8201;dissolution&#8201;medium</mml:mtext></mml:mrow><mml:mrow><mml:mtext>standard&#8201;absorbance</mml:mtext><mml:mo>&#215;</mml:mo><mml:mn>1000</mml:mn></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mtext>standard&#8201;concentrat</mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mtext>on</mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>%</mml:mo><mml:mtext>&#8201;drug&#8201;release</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>amount&#8201;release</mml:mtext></mml:mrow><mml:mrow><mml:mtext>total&#8201;drug&#8201;used&#8201;in&#8201;the&#8201;formulation</mml:mtext></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p></sec><sec id="sec2.6"><title>2.6. Release Kinetics</title><p>To acquire a better understanding of the drug release mechanism from SLN formulation, the data from the in vitro drug release study were fitted into several kinetic models, including zero-order (cumulative% drug release vs. time), First-order (log% drug remaining vs. time), and Higuchi's models (cumulative% drug release vs. square root of time). The regression analysis of the linear curve produced by the previous plots was used to compute the values of <italic toggle="yes">K</italic> and <italic toggle="yes">R</italic><sup>2</sup>. Then, the exact mechanism of drug release was determined from the release exponent value (<italic toggle="yes">n</italic>) of Korsmeyer&#8211;Peppas model (log % drug release vs. log time) [<xref rid="B52" ref-type="bibr">52</xref>&#8211;<xref rid="B55" ref-type="bibr">55</xref>].</p></sec><sec id="sec2.7"><title>2.7. Solid-State Characterization</title><sec id="sec2.7.1"><title>2.7.1. Differential Scanning Calorimetry (DSC)</title><p>The Exstar DSC7020, Hitachi HTG, Japan, was used to record DSC thermograms of pure drug TNF, physical mixture of drug and excipients, and optimal formulation (TF10). All samples were heated in an inert atmosphere created by flushing nitrogen gas with a flow rate of 40&#8201;mL per minute within a hermetically sealed aluminum pan under a constant temperature of 10&#176;C/min from 30&#8211;300&#176;C [<xref rid="B56" ref-type="bibr">56</xref>&#8211;<xref rid="B58" ref-type="bibr">58</xref>].</p></sec><sec id="sec2.7.2"><title>2.7.2. Powder X-Ray Diffractometry (PXRD)</title><p>A Rigaku Miniflex 600, Rigaku Corporation, Japan, model x-ray diffractometer was used to obtain XRD patterns of TNF, physical mixture of TNF and Compritol 888 ATO, poloxamer 188, and improved SLN formulation. The generator had a voltage of 40&#8201;KV and a current of 15&#8201;mA, employing Cu as the anode substance. Every sample was put through CuK<italic toggle="yes">&#945;</italic> radiation at a rate of 0.0200 deg each step over two angles ranging from 3&#176; to 90&#176;. The acquired PXRD patterns were compared to the pure drug's typical drug peak intensity [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>].</p></sec><sec id="sec2.7.3"><title>2.7.3. Scanning Electron Microscopy (SEM)</title><p>Utilizing the VEGA 3, SBH, TESCAN Brno S.R.O., Czech Republic, type scanning electron microscope, the optimized batch of TNF-loaded SLNs (TF10) was examined for surface characteristics and geometry. In brief, the sample was coated in gold and then examined under various magnifications at 15,000&#8201;V accelerating voltage [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B61" ref-type="bibr">61</xref>].</p></sec></sec><sec id="sec2.8"><title>2.8. Ex Vivo Permeation Study Using Gut Sac Method</title><p>Using Franz's diffusion model, an intestinal permeability investigation of optimized TNF-loaded SLNs (TF10) was performed across goat intestines. The jejunal section of a freshly cut goat intestine was carefully isolated and cleaned using 0.98%w/v solution of sodium chloride to get rid of the mucus and lumen contents. The intestine specimen was positioned with its epithelial surface facing upward across the donor and receptor compartments of the Franz diffusing cell after soaking for an hour in saline water. Ten milligrams, or the equivalent, of a drug suspension and optimized TNF-loaded SLN dispersion (TF10) was placed in the donor chamber and wrapped in aluminum foil to avoid drying. Space in the receptor compartment was filled using 10&#8201;mL of pH 7.4 buffer, and the entire unit was held at 37&#8201;&#177;&#8201;0.5&#176;C under constant magnetic stirring. An adequate sample was withdrawn at different time points (0, 0.25, 0.5, 1, 2, 3, 4, 6, and 8) over a period of 8&#8201;h and immediately substituted by an equal amount of new medium, and then, the samples were tested using a UV&#8211;visible spectrophotometer at 262&#8201;nm [<xref rid="B62" ref-type="bibr">62</xref>&#8211;<xref rid="B66" ref-type="bibr">66</xref>].</p></sec><sec id="sec2.9"><title>2.9. In Vivo Bioavailability Study</title><p>Institutional Animal Ethics Committee (IAEC), Hindu College of Pharmacy, Andhra Pradesh, India, approved the study protocol (IAEC-HCOP/2022/07). Eighteen healthy albino Wistar rats weighing 200&#8211;250&#8201;g were chosen for the experiment and fasted overnight before to the trial. Rats were split at random into three groups, each containing six individuals (<italic toggle="yes">n</italic>&#8201;=&#8201;6). The first group receives pure TNF solution (10&#8201;mg/kg body weight), the second group receives optimized SLN formulation TF10 (dosage equivalent to 10&#8201;mg/kg body weight), and the third group receives solvent control (sterile PB pH 7.4 solution). Using glass capillaries, blood samples (0.5&#8201;mL) were obtained from the retro-orbital plexus at predetermined intervals (0, 0.5, 1, 2, 3, 6, 12, 18, and 24&#8201;h). Upon collecting all of the samples into heparinized microtubes, they were centrifuged for 10 minutes at 5000&#8201;rpm at 4&#176;C. 100&#8201;&#956;L of leftover plasma was separated and analyzed by a standardized HPLC technique [<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>].</p></sec><sec id="sec2.10"><title>2.10. Stability Studies</title><p>A stability chamber (Inlab Equipments, India) was used to evaluate the stability of an optimized TNF-loaded SLN (TF10) formulation depending on %EE, average PS, and ZP. For 90&#8201;days, the SLN suspensions were packed in screw-capped amber-tinted glass bottles and stored at three distinct temperatures: 2&#8211;8&#176;C, 25&#8201;&#177;&#8201;2&#176;C/65&#8201;&#177;&#8201;5%RH, and 40&#8201;&#177;&#8201;2&#176;C/75&#8201;&#177;&#8201;5%RH. The average particle diameter, ZP, and %EE of the samples were measured at predefined intervals (1, 30, 60, and 90&#8201;days). The results of these parameters before and after storage are contrasted [<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>].</p></sec></sec><sec id="sec3"><title>3. Results and Discussion</title><sec id="sec3.1"><title>3.1. Lipid Phase Screening</title><p>The drug's capacity to dissolve within a lipid matrix represents a critical parameter, given its influence on both the drug loading capacity and stability of SLNs. The solubility of the drug was assessed across eight different lipids: GMS, SA, cholesterol, Compritol, beeswax, stearyl alcohol, GPS, and CP, with the results depicted in <xref rid="fig2" ref-type="fig">Figure 2</xref>. TNF exhibited solubility in the following order: Compritol&#8201;&gt;&#8201;SA&#8201;&gt;&#8201;GMS&#8201;&gt;&#8201;GPS&#8201;&gt;&#8201;CP&#8201;&gt;&#8201;cholesterol&#8201;&gt;&#8201;stearyl alcohol&#8201;&gt;&#8201;beeswax.</p><p>Among the lipids examined, Compritol 888 ATO demonstrated the highest solubility for TNF, with 180&#8201;mg of TNF solubilized per 1&#8201;g of lipid. SA exhibited the next greatest solubilizing capacity, with 130&#8201;mg of TNF solubilized per 1&#8201;g of lipid. Compritol 888 ATO is a class of acylglycerols derived from behenate and is comprised of a combination of three glycerides: behenic acid mono-, di-, and triglycerides. This lipid forms less ordered crystals, providing more space to accommodate larger quantities of drugs [<xref rid="B73" ref-type="bibr">73</xref>]. This characteristic may account for its notable solubility toward TNF, as confirmed by tests for %EE. Consequently, the lipid phase employed in the subsequent formulation of TNF-loaded SLNs was determined to be Compritol 888 ATO.</p></sec><sec id="sec3.2"><title>3.2. Screening of Surfactant</title><p>Surfactant plays a crucial role in stabilizing SLNs in aqueous environments [<xref rid="B74" ref-type="bibr">74</xref>]. A comprehensive screening of various surfactants, namely, Span 60, Tween 80, poloxamer 188, and poloxamer 407, was conducted. The outcomes of this surfactant assessment, depicted in <xref rid="fig2" ref-type="fig">Figure 2</xref>, were based on the average particle diameter and %EE. The surfactants were ranked according to reduced PS and augmented EE, with the order being poloxamer 188&#8201;&gt;&#8201;Tween 80&#8201;&gt;&#8201;poloxamer 407&#8201;&gt;&#8201;Span 60.</p><p>SLNs formulated with poloxamer 188 exhibited the smallest particle diameter and the highest EE among all tested surfactants. This outcome may be attributed to the comparatively lower molecular weight of poloxamer 188 in comparison with poloxamer 407, as well as its superior HLB value relative to other surfactants. The inherent hydrophilic properties of TNF (log P &#8722;1.6) [<xref rid="B6" ref-type="bibr">6</xref>] likely contributed to the enhanced entrapment when using poloxamer 188 as a surfactant. As a result, the GRAS status of poloxamer 188 [<xref rid="B75" ref-type="bibr">75</xref>] further justified its selection as the preferred surfactant for the subsequent formulation of TNF-loaded SLNs.</p></sec><sec id="sec3.3"><title>3.3. Screening of Formulation Technique</title><p>In a research context, SLN formulations were generated through different methods, namely, solvent evaporation, microemulsion, and HPH. The average PS and drug entrapment efficacy (EE) were evaluated for each technique, and the outcomes are graphically represented in <xref rid="fig2" ref-type="fig">Figure 2</xref>. Notably, the microemulsion approach yielded NPs characterized by diminutive dimensions and high drug EE. Given the hydrophilic nature of TNF, the microemulsion technique presents a distinct advantage in facilitating elevated drug loading [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B76" ref-type="bibr">76</xref>]. On the other hand, the HPH technique yielded nanometer-sized particles but with reduced EE, which may be attributable to the potential disruption of the outer stabilizer coat and lipid core, subsequently leading to drug leaching [<xref rid="B77" ref-type="bibr">77</xref>]. The use of organic solvents in the solvent evaporation process poses a significant toxicological challenge [<xref rid="B78" ref-type="bibr">78</xref>]. Consequently, the microemulsion approach is deemed the optimal method for the generation of TNF-loaded SLNs, characterized by its simplicity, reliability, and suitability for laboratory-scale production. Consequently, subsequent investigations were conducted utilizing the microemulsion technique.</p></sec><sec id="sec3.4"><title>3.4. Drug and Excipient Compatibility Study</title><p>The FTIR spectra depicting the pure drug TNF and the physical mixture are presented in <xref rid="fig3" ref-type="fig">Figure 3</xref>. The significant peaks observed in the IR spectra of TNF are at 3741&#8201;cm<sup>&#8722;1</sup> (O-H stretching), 2984&#8201;cm<sup>&#8722;1</sup> (C-H stretching, alkane), 1755&#8201;cm<sup>&#8722;1</sup> (C=O stretching, ester), 1258&#8201;cm<sup>&#8722;1</sup> (C-O stretching, alcohol), and 785&#8201;cm<sup>&#8722;1</sup> (C-H bending). Upon comparison of the IR spectra of the drug and physical mixture, it was noted that there were no observable shifts or loss of functional peaks, indicating the absence of any substantial reaction between the drug (TNF) and the chosen excipients.</p></sec><sec id="sec3.5"><title>3.5. Method of Preparation</title><p>As per the experimental design outlined in <xref rid="tab2" ref-type="table">Table 2</xref>, 13 formulations of TNF-loaded SLNs were prepared following the specified procedure. Subsequently, these formulations underwent evaluation for particle diameter, PDI, ZP, and %EE.</p></sec><sec id="sec3.6"><title>3.6. Characterization of Formulated TNF-Loaded SLNs</title><sec id="sec3.6.1"><title>3.6.1. PS, PDI, and ZP</title><p>The data presented in <xref rid="tab3" ref-type="table">Table 3</xref> pertain to the PS, PDI, and ZP of SLNs encapsulating TNF. It is observed that the average PS, PDI, and ZP of all 13 formulations ranged between 79.09 and 993.84&#8201;nm, 0.151 and 0.580, and &#8722;5.74 and &#8722;24.09&#8201;mV, respectively. Notably, despite all SLN dispersions exhibiting an average PS below 1000&#8201;nm, the sizes varied depending on the concentration of lipid and emulsifier. Moreover, all formulations demonstrated low PDI values, indicative of a narrow PS distribution. Furthermore, owing to the specific chemical composition of the lipid and surfactant employed, all SLN dispersions showcased a negative ZP, signifying the formulation's stability against aggregation.</p><p>When transporting SLNs, it is advisable to utilize the lymphatic system and ensure that their size falls within the range of 0.3&#8211;1.0&#8201;&#956;m [<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>]. A crucial aspect of formulation stability lies in the ZP, with a minimum ZP of &#177;20&#8201;mv being sought for maximal NP stability [<xref rid="B24" ref-type="bibr">24</xref>]. Enhanced ZP values yield stronger repulsive forces, thereby deterring particle aggregation and bolstering system stability. The PDI assesses the PS distribution around the mean, and a PDI value of less than 0.5 is deemed optimal for NPs [<xref rid="B32" ref-type="bibr">32</xref>]. These considerations warrant attention when choosing an optimized formulation. PS specifications for the majority of formulations indicated dimensions of less than 600&#8201;nm, signifying that the resulting SLNs were well suited for lymphatic transit, potentially accounting for heightened bioavailability. The NPs demonstrated exceptional stability and exhibited narrow size dispersion, as indicated by a PDI of less than 0.5 and ZP values exceeding 15&#8201;mV.</p></sec></sec><sec id="sec3.7"><title>3.7. Effect of Variables on PS, PDI, and ZP</title><sec id="sec3.7.1"><title>3.7.1. Effect of Lipid Concentration</title><p>The concentration of lipids directly influences the size of particles, with PS increasing in direct proportion to the lipid concentration. Notably, formulations with higher lipid content (TF3, 7, 8, and 13) exhibit larger PSs (ranging from 600 to 1000&#8201;&#956;m) compared to formulations with lower lipid content (TF2, 4, 9, and 12), which display PSs ranging from 10 to 100&#8201;&#956;m. The study posits that in SLN formulations, PS escalates with heightened lipid concentration, potentially attributed to the notable interfacial tension between the aqueous and lipid phases, causing globules to coalesce and consequently yielding larger PSs [<xref rid="B52" ref-type="bibr">52</xref>]. Observations of the PDI values suggest that the lipid concentration has no discernible impact on the PDI values of the various formulations under investigation. Alternatively, the measured ZP values indicate that an elevation in the lipid concentration corresponds to an increase in ZP, likely due to heightened interfacial tension and increased ester groups of lipids associated with amplified lipid load [<xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec3.7.2"><title>3.7.2. Effect of Surfactant Concentration</title><p>The PS is notably affected by the quantity of surfactant employed. A substantial reduction in PS is observed with an increase in surfactant content to 2%w/v in formulations TF3, 5, 11, and 12 and TF2, 4, 7, and 10. However, a contrary effect is noted with a further increase in surfactant concentration (3%w/v) in TF1, 6, 8, 9, and 13, resulting in an escalation in particle dimensions due to micelle generation [<xref rid="B81" ref-type="bibr">81</xref>]. The PDI exhibits a concurrent rise with surfactant concentration, which may be attributed to decreased surface tension, facilitating particle partitioning during homogenization. Notably, the ZP appears unaffected by the surfactant concentration.</p></sec><sec id="sec3.7.3"><title>3.7.3. Effect of Homogenization Time</title><p>An increase in homogenization time was shown to result in a decrease in PS. This is explained by the force of droplet deformation increasing with larger homogenization cycles. Batches SLN1&#8211;SLN13 were created by varying the stirring time from 30 to 90&#8201;min. It was found that when homogenization time was increased from 30 to 60&#8201;min, the PS decreased gradually (TF4, 6, 7, and 11 and TF3, 8, 9, 10, and 12). Further increases in homogenization time (up to 90&#8201;min) (TF1, 2, 5, and 13) had no effect. However, the PDI increased with an increase in homogenization time. This may be due to the formation of foam at higher homogenization cycles. Moreover, homogenization for a longer time may lead to particle destabilization, resulting in particle aggregation and an increase in PDI values [<xref rid="B70" ref-type="bibr">70</xref>]. It may be inferred from the observed values of ZP that there was no significant relationship between homogenization time and ZP.</p></sec></sec><sec id="sec3.8"><title>3.8. EE</title><p>The EE determinations are summarized in <xref rid="tab3" ref-type="table">Table 3</xref>. The SLN dispersions loaded with TNF exhibited EEs ranging from 22.24% to 83.93%.</p><sec id="sec3.8.1"><title>3.8.1. Effect of Variables on EE</title><p>The study revealed that higher levels of lipids in the formulation were associated with increased EE. This phenomenon can be attributed to the heightened viscosity, which restricts drug migration into the surrounding dispersion medium. Additionally, a higher lipid concentration provides greater capacity to accommodate the drug, resulting in enhanced EE. However, exceeding a lipid concentration of 5% was found to diminish EE. Notably, formulations TF3, 7, 8, and 13, containing 10% w/v of lipids, exhibited reduced EE, likely due to expeditious lipid solidification and the subsequent partitioning of the hydrophilic drug TNF from the lipid matrix [<xref rid="B82" ref-type="bibr">82</xref>].</p><p>The addition of surfactant to SLN formulations has been reported to significantly enhance EE, particularly for hydrophilic drugs. The analysis of the data presented in <xref rid="tab3" ref-type="table">Table 3</xref> reveals a notable increase in EE from 70.90% to 81.55% with a substantial rise in the surfactant concentration. This enhancement is attributed to improved drug solubilization and its strong interaction with the internal lipid phase. However, when the surfactant concentration exceeds 2%w/v, the drug may form a micellar solution, leading to decreased entrapment percentage [<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>]. Furthermore, extended homogenization times are observed to diminish EE due to the potential distortion of the outer stabilizer coat and lipid core, causing the drug to leach into the external phase [<xref rid="B70" ref-type="bibr">70</xref>].</p><p>The investigated factors, including lipid and surfactant concentrations, as well as homogenization time, yield a significant impact on dependent variables such as particle dimensions and %EE. A marked reduction in PS is associated with decreased lipid and increased surfactant concentrations and longer homogenization times. Conversely, elevated percentage entrapment is linked to higher lipid and surfactant concentrations and reduced homogenization time.</p></sec></sec><sec id="sec3.9"><title>3.9. Data Analysis for Optimization</title><p>The empirical data were scrutinized by applying various models to the observed responses of 13 formulations using the STAT-EASE 360 trial version. After careful examination, it was determined that quadratic models provided the most accurate representation for the analyzed responses, particularly in relation to mean PS and %EE. Subsequently, the generated quadratic equations for the diverse responses are documented as follows:<disp-formula id="EEq3"><label>(3)</label><mml:math id="M3" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mtext>particle&#8201;size</mml:mtext><mml:mo>=</mml:mo><mml:mo>+</mml:mo><mml:mn>449.90</mml:mn><mml:mo>+</mml:mo><mml:mn>360.66</mml:mn><mml:mi mathvariant="normal">A</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>9.69</mml:mn><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mn>7.78</mml:mn><mml:mi mathvariant="normal">C</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>52.55</mml:mn><mml:mtext>&#8201;</mml:mtext><mml:mi mathvariant="normal">B</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>0.1750</mml:mn><mml:mtext>&#8201;</mml:mtext><mml:mi mathvariant="normal">C</mml:mi><mml:mo>+</mml:mo><mml:mn>2.27</mml:mn><mml:mtext>&#8201;</mml:mtext><mml:mi mathvariant="normal">C</mml:mi><mml:mo>&#8722;</mml:mo><mml:msup><mml:mrow><mml:mn>42.50</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mn>85.35</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2.37</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>%</mml:mo><mml:mtext>entrapment&#8201;efficiency</mml:mtext><mml:mo>=</mml:mo><mml:mo>+</mml:mo><mml:mn>81.55</mml:mn><mml:mo>+</mml:mo><mml:mn>21.90</mml:mn><mml:mi mathvariant="normal">A</mml:mi><mml:mo>+</mml:mo><mml:mn>3.80</mml:mn><mml:mi mathvariant="normal">B</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>4.81</mml:mn><mml:mi mathvariant="normal">C</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>6.70</mml:mn><mml:mtext>AB</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mn>1.24</mml:mn><mml:mtext>AC</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mn>1.37</mml:mn><mml:mtext>BC</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mn>18.79</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>6.37</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>5.91</mml:mn><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where A, B, and C represent the codified values for lipid level, surfactant quantity, and homogenization time, respectively.</p><p>Tables <xref rid="tab4a" ref-type="table">4a</xref> and <xref rid="tab4b" ref-type="table">4b</xref> present the ANOVA findings for the %EE and PS, respectively. Model variables A (lipid concentration), B (surfactant concentration), and C (homogenization duration) are significant, according to the ANOVA table for PS, which also shows that the model <italic toggle="yes">F</italic> value of 14.58 is significant with a <italic toggle="yes">p</italic> value of less than 0.05. However, there was no significance found for the model variables AB, AC, BC, A2, B2, and C2. Model terms A (lipid concentration), B (surfactant concentration), C (homogenization duration), AB, A2, B2, and C2 are significant, according to the ANOVA table for %EE, where the model F value of 86.9 is significant with a <italic toggle="yes">p</italic> value of less than 0.05. Model terms AC and BC, however, had no significance. PS and % EE had <italic toggle="yes">R</italic><sup>2</sup> values of 0.9106 and 0.9847, respectively, in <xref rid="tab5" ref-type="table">Table 5</xref>, demonstrating a high association between the formulation factors and response parameters.</p><sec id="sec3.9.1"><title>3.9.1. Response Surface Plots</title><p>Contour and response surface models were utilized to elucidate the correlation between dependent and independent variables, as depicted in <xref rid="fig4" ref-type="fig">Figure 4</xref>. The analysis revealed the statistically significant influence of lipid concentration, surfactant content, and homogenization duration based on the 3D surface plots. The findings indicate that elevating lipid concentration positively influences PS and % EE, resulting in larger PS and higher % entrapment. Conversely, the increased surfactant content yields smaller PS and increased entrapment. Notably, the homogenization duration was found to have negligible effects on PS or % entrapment.</p><p>According to the Design-Experiment software, the most optimal formulation for achieving a high% EE and low mean PS entails utilizing a lipid concentration of 5.5%, a surfactant concentration of 2%, and a homogenization period of 60&#8201;min. In addition, a verification run was conducted to ensure the statistical dependability.</p></sec><sec id="sec3.9.2"><title>3.9.2. Experimental Validation of Design Space</title><p>The superimposed plots depicted in <xref rid="fig3" ref-type="fig">Figure 3</xref> delineate the design space and optimization parameters as prescribed by the DOE methodology to achieve specified targets. Batches were systematically manufactured and subjected to analysis for the determination of particle diameter and percent entrapment based on the defined parameters (illustrated in <xref rid="fig3" ref-type="fig">Figure 3</xref>). Remarkably, the values obtained from the batches closely approximated the projected values, exhibiting minimal bias (+0.637 for PS and +0.730 for percent entrapment, respectively). This convergence indicates the robustness and dependability of the optimization protocol.</p></sec></sec><sec id="sec3.10"><title>3.10. Drug Release Studies</title><p>
<xref rid="fig5" ref-type="fig">Figure 5</xref> illustrates the in vitro release profile of pure TNF solution and various TNF-loaded SLN formulations. The cumulative release of TNF after 24&#8201;h ranged from 71.87% to 99.68% for the SLN dispersions, whereas the pure drug solution achieved nearly complete drug release within 4&#8201;h. Notably, TNF release from SLN dispersions exhibited a biphasic pattern, characterized by an initial burst release of approximately 24.38%&#8211;40.06% within the first 4&#8201;hours, followed by a sustained release. The study findings emphasize that higher lipid content in the SLNs is associated with delayed medication release, potentially offering extended therapeutic benefits. The initial burst release within four hours is postulated to result from drug adsorption on the surface of the SLNs, while the subsequent steady release for up to 24 hours is attributed to a diffusion mechanism slowly releasing the solubilized drug from the lipid matrix [<xref rid="B83" ref-type="bibr">83</xref>].</p></sec><sec id="sec3.11"><title>3.11. Release Kinetics</title><p>The in vitro release profiles were assessed using various kinetic models including zero-order, first-order, Higuchi, and Korsmeyer&#8211;Peppas models to characterize the release behavior. The determination of the goodness of fit for each model was based on the correlation coefficient (<italic toggle="yes">R</italic><sup>2</sup>) values, with the model exhibiting the highest <italic toggle="yes">R</italic><sup>2</sup> value considered to be most representative of the release kinetics. It was observed that all formulations displayed a higher correlation coefficient for the first-order model, followed by the Higuchi model. These findings suggest that drug diffusion from the lipid matrix governs the release of the drug from SLNs. Additionally, the Korsmeyer&#8211;Peppas model revealed a release exponent (<italic toggle="yes">n</italic>) value smaller than 0.5, indicating that TNF is released from SLNs via Fickian diffusion.</p></sec><sec id="sec3.12"><title>3.12. Solid-State Characterization</title><sec id="sec3.12.1"><title>3.12.1. DSC</title><p>DSC thermographs of TNF, a physical composite of TNF and Compritol 888 ATO, and the optimized TNF-loaded SLN formulation (TF10) are displayed in <xref rid="fig6" ref-type="fig">Figure 6</xref>. TNF has a prominent endothermic peak at 120&#176;C on the DSC thermograph, confirming its melting point. The DSC thermograph for the physical mixture (TNF&#8201;+&#8201;Compritol 888 ATO) showed two endothermic maxima at 72&#176;C and 120&#176;C, correlated to the melting temperatures of TNF and Compritol 888 ATO, respectively. The appearance of two distinct peaks for the physical combination and no alteration in the endothermic peak of TNF show that TNF and the lipid (Compritol 888 ATO) have no chemical interactions. The DSC thermograph for optimized TNF-loaded SLNs shows only one endothermic peak at 72&#176;C for Compritol 888 ATO, and the peak for pure drug TNF disappeared. This indicates that TNF is molecularly entrapped in the lipid matrix.</p></sec><sec id="sec3.12.2"><title>3.12.2. PXRD</title><p>The PXRD spectra of TNF, a physical mixture of TNF and Compritol 888 ATO, and optimized TNF-loaded SLN formulation (TF10) are shown in <xref rid="fig7" ref-type="fig">Figure 7</xref>. The x-ray diffractogram of pure TNF showed strong peaks, indicating its crystalline nature. These peaks were likewise present with the same strength in the physical mixture but not in the TNF-loaded SLN diffractogram. This implies that the medication is totally miscible with the lipid matrix (Compritol 888 ATO) at the molecular level.</p></sec><sec id="sec3.12.3"><title>3.12.3. SEM</title><p>The SEM analysis was applied to examine the dimensions and surface texture of optimized TNF-loaded SLNs. In <xref rid="fig8" ref-type="fig">Figure 8</xref>, SEM photomicrographs show that the formulated SLNs have a uniform size, smooth surface morphology, and spherical shape. The particles have a sealed SLN structure and no visible aggregation.</p></sec></sec><sec id="sec3.13"><title>3.13. Ex Vivo Permeation Studies</title><p>The comparison of TNF's permeation profile is depicted in <xref rid="fig4" ref-type="fig">Figure 4</xref>, contrasting a pure drug suspension and TNF-loaded SLNs across a goat intestinal section. The ex vivo diffusion study, conducted for a duration of 8&#8201;h, unveiled that merely 19.36&#8201;&#177;&#8201;1.31% of the drug diffused from the TNF suspension, while an impressive 97.15&#8201;&#177;&#8201;0.90% of the drug permeated from the TNF-loaded SLNs. A notable outcome arising from the ex vivo permeation studies indicated that the apparent permeability coefficient (Papp) of TNF-loaded SLNs stood at 0.176&#8201;&#215;&#8201;10<sup>&#8722;6</sup>&#8201;cm/s, a significant increase compared to the 0.012&#8201;&#215;&#8201;10<sup>&#8722;6</sup>&#8201;cm/s Papp of the TNF suspension. The hydrophobic nature of the lipid matrix, in which the medication is enclosed, facilitates transport through the microfold cells within the intestinal epithelium, elucidating the considerable enhancement in the permeability of TNF-loaded SLNs in contrast to the bulk drug [<xref rid="B48" ref-type="bibr">48</xref>].</p></sec><sec id="sec3.14"><title>3.14. In Vivo Bioavailability Study</title><p>In <xref rid="fig9" ref-type="fig">Figure 9</xref>, the oral pharmacokinetic properties of pure TNF and TNF-loaded SLNs are compared. The area under the curve (AUC), maximum drug levels in plasma (<italic toggle="yes">C</italic><sub>max</sub>), and the duration to reach peak level (<italic toggle="yes">T</italic><sub>max</sub>) were computed utilizing the linear-log trapezoidal approach based on the plasma concentration (Cp) vs. time profile graph. The results in <xref rid="tab6" ref-type="table">Table 6</xref> indicate that <italic toggle="yes">T</italic><sub>max</sub>, <italic toggle="yes">C</italic><sub>max</sub>, <italic toggle="yes">K</italic><sub><italic toggle="yes">a</italic></sub>, <italic toggle="yes">t</italic><sub>1/2</sub>, mean residence time (MRT), and AUC values were notably higher with TNF-loaded SLNs as compared to pure TNF, signifying a substantial increase in oral bioavailability. Despite ex vivo permeation experiments demonstrating elevated permeability, this does not necessarily correlate to improved drug absorption. As a result, in vivo pharmacokinetic experiments were conducted, confirming a 12.4-fold increase in bioavailability compared to the pure TNF solution. The amplified bioavailability of TNF-loaded SLNs could be attributed to lymphatic uptake by M cells in Peyer's patch, improved penetration across the gastrointestinal (GI) membrane, inhibition of P-gp efflux transport, and increased paracellular transport induced by the lipid matrix [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B84" ref-type="bibr">84</xref>].</p></sec><sec id="sec3.15"><title>3.15. Stability Studies</title><p>The stability of optimized TNF-loaded SLN formulation was tested under various storage conditions, and the findings are reported in <xref rid="tab7" ref-type="table">Table 7</xref>. At 25&#8201;&#177;&#8201;2&#176;C/65&#8201;&#177;&#8201;5%RH and 2&#8211;8&#176;C, no changes in physical appearance, particle dimensions, % EE, and ZP were noted during 3&#8201;months. At 40&#8201;&#177;&#8201;2&#176;C/755%RH, there had been a modest rise in the particle diameter and a drop in EE although this may not be relevant. These findings show that the formulation produced is stable and has a long shelf life.</p></sec></sec><sec id="sec4"><title>4. Conclusion</title><p>The study delineated the advantages of systematically screening lipid, surfactant, and formulation techniques to enhance the loading capacity of hydrophilic drugs in SLNs. The challenge of encapsulating hydrophilic drugs within the hydrophobic matrix of SLNs, attributed to these drugs' tendency to migrate into the aqueous phase during the manufacturing process, was addressed. The study successfully developed SLNs loaded with the hydrophilic antiviral drug TNF (BCS Class III) using the microemulsion process with Compritol as the lipid, employing the BBD. The resulting SLNs demonstrated a PS of 449.90&#8201;&#177;&#8201;4.79&#8201;nm and an EE of 83.13&#8201;&#177;&#8201;6.34%. The investigation disclosed a 12.4-fold increase in bioavailability for TNF-loaded SLNs compared to pure TNF solution, as observed in albino Wistar rats. This suggests that SLNs could serve as carriers to enhance the bioavailability of BCS Class III medicines (hydrophilic pharmaceuticals), considering their limited oral bioavailability attributed to permeability constraints.</p><sec id="sec4.1"><title>4.1. Future Perspective</title><p>The researchers contemplate assessing the in vivo performance of TNF-loaded SLNs to evaluate the formulation's potential in managing HIV infections. Furthermore, they plan to investigate the influence of surface charge on SLN lymphatic absorption. This groundbreaking discovery is anticipated to offer a platform technology for augmenting the delivery of therapeutic compounds demonstrating low bioavailability due to limited permeability, gut metabolism, and P-gp efflux transport, particularly antiviral medications.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge MSN Laboratories Pvt. Ltd. for supplying tenofovir and Compritol 888 ATO as complimentary samples. The authors also acknowledge the management of SRM College of Pharmacy, Chennai, and Hindu College of Pharmacy, Guntur, for building essential requirements and technical assistance.</p></ack><sec sec-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec><title>Ethics Statement</title><p>The study was approved by the Institutional Animal Ethics Committee Hindu College of Pharmacy, Guntur, AP, India (IAEC-HCOP/2022/07), and their guidelines were followed throughout the study.</p></sec><sec><title>Disclosure</title><p>The content and writing of this work are solely the responsibility of the authors.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Author Contributions</title><p>Sangeetha S. helped with conceptualization and supervision. Sri Rekha M. contributed to the formal analysis and resources, methodology, and original draft preparation. All authors have read and approved the manuscript.</p></sec><sec><title>Funding</title><p>No funding was received for this manuscript.</p></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soler-Palac&#237;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Melendo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noguera-Julian</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prospective Study of Renal Function in HIV-Infected Pediatric Patients Receiving Tenofovir-Containing HAART Regimens</article-title><source><italic toggle="yes">Acquired Immunodeficiency Syndrome</italic></source><year>2011</year><volume>25</volume><issue>2</issue><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328340fdca</pub-id><pub-id pub-id-type="other">2-s2.0-78650903833</pub-id><pub-id pub-id-type="pmid">21076275</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz de Benito</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Arribas L&#243;pez</surname><given-names>J. R.</given-names></name></person-group><article-title>Tenofovir Disoproxil Fumarate Emtricitabine Coformulation for Once-Daily Dual NRTI Backbone</article-title><source><italic toggle="yes">Expert Review of Anti-infective Therapy</italic></source><year>2006</year><volume>4</volume><issue>4</issue><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1586/14787210.4.4.523</pub-id><pub-id pub-id-type="other">2-s2.0-33749524821</pub-id><pub-id pub-id-type="pmid">17009933</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>C. M.</given-names></name></person-group><article-title>Emtricitabine/Tenofovir Disoproxil Fumarate: In Combination With a Protease Inhibitor in HIV-1 Infection</article-title><source><italic toggle="yes">Drugs</italic></source><year>2009</year><volume>69</volume><issue>7</issue><fpage>843</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.2165/00003495-200969070-00005</pub-id><pub-id pub-id-type="other">2-s2.0-66149100884</pub-id><pub-id pub-id-type="pmid">19441871</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhavsar</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>C. N.</given-names></name></person-group><article-title>RP-HPLC Method for Simultaneous Estimation of Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz in Combined Tablet Dosage Form</article-title><source><italic toggle="yes">Pharmaceutical Methods</italic></source><year>2012</year><volume>3</volume><issue>2</issue><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4103/2229-4708.103876</pub-id><pub-id pub-id-type="pmid">23781482</pub-id><pub-id pub-id-type="pmcid">PMC3658085</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallant</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Staszewski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pozniak</surname><given-names>A. L.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial</article-title><source><italic toggle="yes">Journal of the American Medical Association</italic></source><year>2004</year><volume>292</volume><issue>2</issue><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1001/jama.292.2.191</pub-id><pub-id pub-id-type="other">2-s2.0-3042848853</pub-id><pub-id pub-id-type="pmid">15249568</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shailender</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Mrinalini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avantika</surname><given-names>D.</given-names></name><name name-style="western"><surname>Keerthi Priya</surname><given-names>O.</given-names></name></person-group><article-title>Chitosan Nanoparticles for the Oral Delivery of Tenofovir Disoproxil Fumarate: Formulation Optimization, Characterization and Ex Vivo and In Vivo Evaluation for Uptake Mechanism in Rats</article-title><source><italic toggle="yes">Drug Development and Industrial Pharmacy</italic></source><year>2018</year><volume>44</volume><fpage>1520</fpage><lpage>5762</lpage><pub-id pub-id-type="pmid">29409342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03639045.2018.1438459</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S. U.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R. J. Y.</given-names></name></person-group><article-title>pH-Dependent Interactions of Indinavir and Lipids in Nanoparticles and Their Ability to Entrap a Solute</article-title><source><italic toggle="yes">Journal of Pharmaceutical Sciences</italic></source><year>2008</year><volume>97</volume><issue>2</issue><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1002/jps.21020</pub-id><pub-id pub-id-type="other">2-s2.0-39749120051</pub-id><pub-id pub-id-type="pmid">17546665</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kearney</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>J.</given-names></name></person-group><article-title>Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics</article-title><source><italic toggle="yes">Clinical Pharmacokinetics</italic></source><year>2004</year><volume>43</volume><issue>9</issue><fpage>595</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.2165/00003088-200443090-00003</pub-id><pub-id pub-id-type="other">2-s2.0-3242694930</pub-id><pub-id pub-id-type="pmid">15217303</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Gelder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deferme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Increased Absorption of the Antiviral Ester Prodrug Tenofovir Disoproxil in Rat Ileum by Inhibiting Its Intestinal Metabolism</article-title><source><italic toggle="yes">Drug Metabolism &amp; Disposition</italic></source><year>2000</year><volume>28</volume><issue>12</issue><fpage>1394</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">11095573</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Oliyai</surname><given-names>R.</given-names></name></person-group><article-title>Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution</article-title><source><italic toggle="yes">Pharmaceutical Research</italic></source><year>2001</year><volume>18</volume><issue>2</issue><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1023/a:1011044804823</pub-id><pub-id pub-id-type="other">2-s2.0-0034949184</pub-id><pub-id pub-id-type="pmid">11405296</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barditch-Crovo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2001</year><volume>45</volume><issue>10</issue><fpage>2733</fpage><lpage>2739</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.10.2733-2739.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034806946</pub-id><pub-id pub-id-type="pmid">11557462</pub-id><pub-id pub-id-type="pmcid">PMC90724</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>D. R.</given-names></name></person-group><article-title>Tenofovir-Induced Renal Tubular Dysfunction Presenting With Hypocalcaemia</article-title><source><italic toggle="yes">Journal of Infection</italic></source><year>2006</year><volume>52</volume><issue>4</issue><fpage>E107</fpage><lpage>E108</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2005.07.014</pub-id><pub-id pub-id-type="other">2-s2.0-33645283053</pub-id><pub-id pub-id-type="pmid">16125779</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>N.</given-names></name></person-group><article-title>Acute Renal Failure and Fanconi Syndrome in an AIDS Patient on Tenofovir Treatment &#8211; Case Report and Review of Literature</article-title><source><italic toggle="yes">Journal of Infection</italic></source><year>2005</year><volume>51</volume><issue>2</issue><fpage>E61</fpage><lpage>E65</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2004.08.031</pub-id><pub-id pub-id-type="other">2-s2.0-22144438662</pub-id><pub-id pub-id-type="pmid">16038754</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicconi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bongiovanni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Melzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tordato</surname><given-names>F.</given-names></name><name name-style="western"><surname>d&#8217;Arminio Monforte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bini</surname><given-names>T.</given-names></name></person-group><article-title>Nephrolithiasis and Hydronephrosis in an HIV-Infected Man Receiving Tenofovir</article-title><source><italic toggle="yes">International Journal of Antimicrobial Agents</italic></source><year>2004</year><volume>24</volume><issue>3</issue><fpage>284</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.04.005</pub-id><pub-id pub-id-type="other">2-s2.0-4344615378</pub-id><pub-id pub-id-type="pmid">15325433</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manjunath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Venkateswarlu</surname><given-names>V.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles as Drug Delivery Systems</article-title><source><italic toggle="yes">Methods and Findings in Experimental and Clinical Pharmacology</italic></source><year>2005</year><volume>27</volume><issue>2</issue><fpage>127</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1358/mf.2005.27.2.876286</pub-id><pub-id pub-id-type="other">2-s2.0-17044390370</pub-id><pub-id pub-id-type="pmid">15834465</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahavir</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sneh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Preeti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tulika</surname><given-names>M.</given-names></name></person-group><article-title>Application of Nanostructures in Antimicrobial Therapy</article-title><source><italic toggle="yes">International Journal of Applied Pharmaceutics</italic></source><year>2018</year><volume>10</volume><issue>4</issue><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.22159/ijap.2018v10i4.25803</pub-id><pub-id pub-id-type="other">2-s2.0-85067803270</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>A.</given-names></name></person-group><article-title>Recent Advances in Lipid Nanoparticle Formulations With Solid Matrix for Oral Drug Delivery</article-title><source><italic toggle="yes">AAPS PharmSciTech</italic></source><year>2011</year><volume>12</volume><issue>1</issue><fpage>62</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1208/s12249-010-9563-0</pub-id><pub-id pub-id-type="other">2-s2.0-79954417472</pub-id><pub-id pub-id-type="pmid">21174180</pub-id><pub-id pub-id-type="pmcid">PMC3066374</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>The Performance of Docetaxelloaded Solid Lipid Nanoparticles Targeted to Hepatocellular Carcinoma</article-title><source><italic toggle="yes">Biomaterials</italic></source><year>2009</year><volume>30</volume><issue>2</issue><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.09.014</pub-id><pub-id pub-id-type="other">2-s2.0-54049157140</pub-id><pub-id pub-id-type="pmid">18851881</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>I. P.</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kakkar</surname><given-names>V.</given-names></name></person-group><article-title>Potential of Solid Lipid Nanoparticles in Brain Targeting</article-title><source><italic toggle="yes">Journal of Controlled Release</italic></source><year>2008</year><volume>127</volume><issue>2</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2007.12.018</pub-id><pub-id pub-id-type="other">2-s2.0-41449091856</pub-id><pub-id pub-id-type="pmid">18313785</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasar</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Kale</surname><given-names>K. S. R.</given-names></name><name name-style="western"><surname>Phadtare</surname><given-names>D. G.</given-names></name></person-group><article-title>Nanoplex: A Review of Nanotechnology Approach for Solubility and Dissolution Rate Enhancement</article-title><source><italic toggle="yes">International Journal of Current Pharmaceutical Research</italic></source><year>2018</year><volume>10</volume><issue>4</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.22159/ijcpr.2018v10i4.28467</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sri Rekha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sangeetha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seetha Devi</surname><given-names>A.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles: A Potential Option for Enhancing Oral Bioavailability of Highly Soluble and Poorly Permeable (BCS Class III) Drugs</article-title><source><italic toggle="yes">Current Drug Delivery</italic></source><year>2022</year><volume>20</volume><fpage>223</fpage><lpage>236</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567201819666220418100410</pub-id><pub-id pub-id-type="pmid">35443896</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekambaram</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sathali</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Priyanka</surname><given-names>K.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles: A Review</article-title><source><italic toggle="yes">Scientific Reviews and Chemical. Communication</italic></source><year>2012</year><volume>2</volume><issue>Suppl 1</issue><fpage>80</fpage><lpage>102</lpage></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehnert</surname><given-names>W.</given-names></name><name name-style="western"><surname>M&#228;der</surname><given-names>K.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles-Production, Characterization and Applications</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2001</year><volume>47</volume><issue>2-3</issue><fpage>165</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(01)00105-3</pub-id><pub-id pub-id-type="other">2-s2.0-0035946615</pub-id><pub-id pub-id-type="pmid">11311991</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dobhal</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name></person-group><article-title>Formulation and Evaluation of Solid Lipid Nanoparticles of a Water Soluble Drug: Zidovudine</article-title><source><italic toggle="yes">Chemical &amp; Pharmaceutical Bulletin</italic></source><year>2010</year><volume>58</volume><issue>5</issue><fpage>650</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1248/cpb.58.650</pub-id><pub-id pub-id-type="other">2-s2.0-77951710606</pub-id><pub-id pub-id-type="pmid">20460791</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khatak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sara</surname><given-names>U. V. S.</given-names></name></person-group><article-title>Lipid Nanoparticles- A Review</article-title><source><italic toggle="yes">International Journal of Applied Pharmaceutics</italic></source><year>2013</year><volume>5</volume><issue>2</issue><fpage>8</fpage><lpage>18</lpage></element-citation></ref><ref id="B26" content-type="book"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Neil</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Heckelman</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Dobbelaar</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Karaffa</surname><given-names>L. S.</given-names></name></person-group><source><italic toggle="yes">The Merck Index: An Encyclopedia of Chemicals, Drugs, and BioLogicals</italic></source><year>2013</year><publisher-loc>Cambridge, UK</publisher-loc><publisher-name>Royal Society of Chemistry</publisher-name></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sentenac</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thuillier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lechat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aymard</surname><given-names>G.</given-names></name></person-group><article-title>Sensitive Determination of Tenofovir in Human Plasma Samples Using Reversedphase Liquid Chromatography</article-title><source><italic toggle="yes">Journal of Chromatography B</italic></source><year>2003</year><volume>793</volume><issue>2</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/s1570-0232(03)00333-7</pub-id><pub-id pub-id-type="other">2-s2.0-0142059555</pub-id><pub-id pub-id-type="pmid">12906906</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacalone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hillaireau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fattal</surname><given-names>E.</given-names></name></person-group><article-title>Improving Bioavailability and Biodistribution of Anti-HIV Chemotherapy</article-title><source><italic toggle="yes">European Journal of Pharmaceutical Sciences</italic></source><year>2015</year><volume>75</volume><fpage>40</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2015.04.011</pub-id><pub-id pub-id-type="other">2-s2.0-84929953648</pub-id><pub-id pub-id-type="pmid">25937367</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shailender</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dalvi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Myneni</surname><given-names>S.</given-names></name></person-group><article-title>Tenofovir Disoproxil Fumarate Loaded PLGA Nanoparticles for Enhanced Oral Absorption: Effect of Experimental Variables and In Vitro, Ex Vivo and In Vivo Evaluation</article-title><source><italic toggle="yes">Colloids and Surfaces B: Biointerfaces</italic></source><year>2017</year><volume>158</volume><fpage>610</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.07.037</pub-id><pub-id pub-id-type="other">2-s2.0-85025652080</pub-id><pub-id pub-id-type="pmid">28755558</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shete</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patravale</surname><given-names>V.</given-names></name></person-group><article-title>Long Chain Lipid Based Tamoxifen NLC. Part I: Preformulation Studies, Formulation Development and Physicochemical Characterization</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2013</year><volume>454</volume><issue>1</issue><fpage>573</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.03.034</pub-id><pub-id pub-id-type="other">2-s2.0-84884153461</pub-id><pub-id pub-id-type="pmid">23535345</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giovagnoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schoubben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>C.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles for Targeted Brain Drug Delivery</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2007</year><volume>59</volume><issue>6</issue><fpage>454</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.04.011</pub-id><pub-id pub-id-type="other">2-s2.0-34547871312</pub-id><pub-id pub-id-type="pmid">17570559</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shweta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rajesh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Narendra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ambikanandan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelwahab</surname><given-names>O.</given-names></name></person-group><article-title>Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability</article-title><source><italic toggle="yes">BioMed Research International</italic></source><year>2017</year><volume>18</volume><fpage>p. 5984014</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/5984014</pub-id><pub-id pub-id-type="pmcid">PMC5294220</pub-id><pub-id pub-id-type="pmid">28243600</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhalekar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Upadhaya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madgulkar</surname><given-names>A.</given-names></name></person-group><article-title>Formulation and Characterization of Solid Lipid Nanoparticles for an Anti-Retroviral Drug Darunavir</article-title><source><italic toggle="yes">Applied Nanoscience</italic></source><year>2017</year><volume>7</volume><issue>1-2</issue><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s13204-017-0547-1</pub-id><pub-id pub-id-type="other">2-s2.0-85051125554</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Gonzalez-Mira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>M. L.</given-names></name><etal/></person-group><article-title>Preparation, Characterization and Biocompatibility Studies on Risperidoneloaded Solid Lipid Nanoparticles (SLN): High Pressure Homogenization versus Ultrasound</article-title><source><italic toggle="yes">Colloids and Surfaces B: Biointerfaces</italic></source><year>2011</year><volume>86</volume><issue>1</issue><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2011.03.035</pub-id><pub-id pub-id-type="other">2-s2.0-79955794727</pub-id><pub-id pub-id-type="pmid">21530187</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Ban</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Development of DHI-180-3 Loaded Lipid Nanoparticle for Photodynamic Therapy</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2015</year><volume>491</volume><issue>1-2</issue><fpage>393</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.07.002</pub-id><pub-id pub-id-type="other">2-s2.0-84937039473</pub-id><pub-id pub-id-type="pmid">26149935</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pani</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhuniya</surname><given-names>B.</given-names></name></person-group><article-title>Application of DSC, IST, and FTIR Study in the Compatibility Testing of Nateglinide With Different Pharmaceutical Excipients</article-title><source><italic toggle="yes">Journal of Thermal Analysis and Calorimetry</italic></source><year>2012</year><volume>108</volume><issue>1</issue><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s10973-011-1299-x</pub-id><pub-id pub-id-type="other">2-s2.0-84858072534</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priyanka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Optimization of Processing Parameters for the Development of <italic toggle="yes">Ficus religiosa</italic> L. Extract Loaded Solid Lipid Nanoparticles Using Central Composite Design and Evaluation of Antidiabetic Efficacy</article-title><source><italic toggle="yes">Journal of Drug Delivery Science and Technology</italic></source><year>2018</year><volume>43</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.08.006</pub-id><pub-id pub-id-type="other">2-s2.0-85030311732</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunasekaran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>K.</given-names></name></person-group><article-title>Compatibility Studies of Rasagiline Mesylate With Selected Excipients for an Effective Solid Lipid Nanoparticles Formulation</article-title><source><italic toggle="yes">International Journal of Pharmacy and Pharmaceutical Sciences</italic></source><year>2015</year><volume>7</volume><issue>1</issue><fpage>73</fpage><lpage>80</lpage></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aqil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mujeeb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name></person-group><article-title>Formulation and Optimization of Nanotransfersomes Using Experimental Design Technique for Accentuated Transdermal Delivery of Valsartan</article-title><source><italic toggle="yes">Nanomedicine: Nanotechnology, Biology and Medicine</italic></source><year>2012</year><volume>8</volume><issue>2</issue><fpage>237</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2011.06.004</pub-id><pub-id pub-id-type="other">2-s2.0-84855854929</pub-id><pub-id pub-id-type="pmid">21704600</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Ahad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imam</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Aqil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name></person-group><article-title>Application of Box&#8211;Behnken Design for Preparation of Levofloxacin-Loaded Stearic Acid Solid Lipid Nanoparticles for Ocular Delivery: Optimization, In Vitro Release, Ocular Tolerance, and Antibacterial Activity</article-title><source><italic toggle="yes">International Journal of Biological Macromolecules</italic></source><year>2016</year><volume>85</volume><fpage>258</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.12.077</pub-id><pub-id pub-id-type="other">2-s2.0-84953312653</pub-id><pub-id pub-id-type="pmid">26740466</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aslam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aqil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Najmi</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name></person-group><article-title>Application of Box&#8211;Behnken Design for Preparation of Glibenclamide Loaded Lipid Based Nanoparticles: Optimization, In Vitro Skin Permeation, Drug Release and In Vivo Pharmacokinetic Study</article-title><source><italic toggle="yes">Journal of Molecular Liquids</italic></source><year>2016</year><volume>219</volume><issue>July</issue><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.molliq.2016.03.069</pub-id><pub-id pub-id-type="other">2-s2.0-84964207158</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiyaboonchai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tungpradit</surname><given-names>W.</given-names></name><name name-style="western"><surname>Plianbangchang</surname><given-names>P.</given-names></name></person-group><article-title>Formulation and Characterization of Curcuminoids Loaded Solid Lipid Nanoparticles</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2007</year><volume>337</volume><issue>1-2</issue><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.12.043</pub-id><pub-id pub-id-type="other">2-s2.0-34248549039</pub-id><pub-id pub-id-type="pmid">17287099</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doijad</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Manvi</surname><given-names>F. V.</given-names></name><name name-style="western"><surname>Godhwani</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>N. V.</given-names></name></person-group><article-title>Formulation and Targeting Efficiency of Cisplatin Engineered Solid Lipid Nanoparticles</article-title><source><italic toggle="yes">Indian Journal of Pharmaceutical Sciences</italic></source><year>2008</year><volume>70</volume><issue>2</issue><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.4103/0250-474X.41456</pub-id><pub-id pub-id-type="other">2-s2.0-46349097542</pub-id><pub-id pub-id-type="pmid">20046713</pub-id><pub-id pub-id-type="pmcid">PMC2792476</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viveksarathi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>K.</given-names></name></person-group><article-title>Multi Criteria Decision Making to Select the Best Method for the Preparation of Solid Lipid Nanoparticles of Rasagiline Mesylate Using Analytic Hierarchy Process</article-title><source><italic toggle="yes">Journal of Advanced Pharmaceutical Technology &amp; Research</italic></source><year>2014</year><volume>5</volume><issue>3</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25126532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2231-4040.137410</pub-id><pub-id pub-id-type="pmcid">PMC4131401</pub-id></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goindi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katare</surname><given-names>O. P.</given-names></name></person-group><article-title>Thermal Analysis and Quantitative Characterization of Compatibility Between Diflunisal and Lipid Excipients as Raw Materials for Development of Solid Lipid Nanoparticles</article-title><source><italic toggle="yes">Thermochimica Acta</italic></source><year>2016</year><volume>643</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.tca.2016.09.014</pub-id><pub-id pub-id-type="other">2-s2.0-84988515837</pub-id></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Dhote</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>P. K.</given-names></name></person-group><article-title>Engineering Solid Lipid Nanoparticles for Improved Drug Delivery: Promises and Challenges of Translational Research</article-title><source><italic toggle="yes">Drug Delivery and Translational Research</italic></source><year>2012</year><volume>2</volume><issue>4</issue><fpage>238</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/s13346-012-0088-9</pub-id><pub-id pub-id-type="other">2-s2.0-84866179878</pub-id><pub-id pub-id-type="pmid">25787030</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhawan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kapil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name></person-group><article-title>Formulation Development and Systematic Optimization of Solid Lipid Nanoparticles of Quercetin for Improved Brain Delivery</article-title><source><italic toggle="yes">Journal of Pharmacy and Pharmacology</italic></source><year>2011</year><volume>63</volume><issue>3</issue><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2010.01225.x</pub-id><pub-id pub-id-type="other">2-s2.0-79952229207</pub-id><pub-id pub-id-type="pmid">21749381</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paliwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Effect of Lipid Core Material on Characteristics of Solid Lipid Nanoparticles Designed for Oral Lymphatic Delivery</article-title><source><italic toggle="yes">Nanomedicine: Nanotechnology, Biology and Medicine</italic></source><year>2009</year><volume>5</volume><issue>2</issue><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2008.08.003</pub-id><pub-id pub-id-type="other">2-s2.0-67349203156</pub-id><pub-id pub-id-type="pmid">19095502</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles for Enhancing Vinpocetine&#8217;s Oral Bioavailability</article-title><source><italic toggle="yes">Journal of Controlled Release</italic></source><year>2006</year><volume>114</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.05.010</pub-id><pub-id pub-id-type="other">2-s2.0-33746626869</pub-id><pub-id pub-id-type="pmid">16828192</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>M.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles of Temozolomide: Potential Reduction of Cardial and Nephric Toxicity</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2008</year><volume>355</volume><issue>1-2</issue><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.12.013</pub-id><pub-id pub-id-type="other">2-s2.0-41349095417</pub-id><pub-id pub-id-type="pmid">18255242</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gnanarajan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Juyal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Kailash</surname><given-names>P.</given-names></name></person-group><article-title>A Validated Method for Development of Tenofovir as API and Tablet Dosage Forms by UV Spectroscopy</article-title><source><italic toggle="yes">Journal of Young Pharmacists</italic></source><year>2009</year><volume>1</volume><issue>4</issue><fpage>351</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.4103/0975-1483.59326</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priyanka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sathali</surname><given-names>A. A.</given-names></name></person-group><article-title>Preparation and Evaluation of Montelukast Sodium Loaded Solid Lipid Nanoparticles</article-title><source><italic toggle="yes">Journal of Young Pharmacists</italic></source><year>2012</year><volume>4</volume><issue>3</issue><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.4103/0975-1483.100016</pub-id><pub-id pub-id-type="other">2-s2.0-84866711353</pub-id><pub-id pub-id-type="pmid">23112531</pub-id><pub-id pub-id-type="pmcid">PMC3483522</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanumanaik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vinod Kumar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiran</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sudhakara Rao</surname><given-names>G.</given-names></name></person-group><article-title>Formulation, Characterization and Evaluation of Solid Lipid Nanoparticles of Selected Antitubercular Agent</article-title><source><italic toggle="yes">IJPSR</italic></source><year>2020</year><volume>11</volume><issue>8</issue><fpage>3734</fpage><lpage>3744</lpage></element-citation></ref><ref id="B54" content-type="article"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravi</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Aditya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kathuria</surname><given-names>H.</given-names></name><name name-style="western"><surname>Malekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vats</surname><given-names>R.</given-names></name></person-group><article-title>Lipid Nanoparticles for Oral Delivery of Raloxifene: Optimization, Stability, In Vivo Evaluation and Uptake Mechanism</article-title><source><italic toggle="yes">European Journal of Pharmaceutics and Biopharmaceutics</italic></source><year>2014</year><volume>87</volume><issue>1</issue><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2013.12.015</pub-id><pub-id pub-id-type="other">2-s2.0-84901610423</pub-id><pub-id pub-id-type="pmid">24378615</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Development and Evaluation of Penciclovir-Loaded Solid Lipid Nanoparticles for Topical Delivery</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2009</year><volume>372</volume><issue>1-2</issue><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2009.01.014</pub-id><pub-id pub-id-type="other">2-s2.0-64149094878</pub-id><pub-id pub-id-type="pmid">19429280</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parrot-Lopez</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>Abdelwahed</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Scanning Electron Microscopy and Atomic Force Microscopy Imaging of Solid Lipid Nanoparticles Derived from Amphiphilic Cyclodextrins</article-title><source><italic toggle="yes">European Journal of Pharmaceutics and Biopharmaceutics</italic></source><year>2003</year><volume>55</volume><issue>3</issue><fpage>279</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/s0939-6411(03)00020-1</pub-id><pub-id pub-id-type="other">2-s2.0-0037723990</pub-id><pub-id pub-id-type="pmid">12754001</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shegokar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gohla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>R. H.</given-names></name></person-group><article-title>Lipid Nanocarriers for Dermal Delivery of Lutein: Preparation, Characterization, Stability and Performance</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2011</year><volume>414</volume><issue>1-2</issue><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.05.008</pub-id><pub-id pub-id-type="other">2-s2.0-79959739491</pub-id><pub-id pub-id-type="pmid">21596122</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marsaud</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bouclier</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Nanoparticles Loaded With Ferrocenyl Tamoxifen Derivatives for Breast Cancer Treatment</article-title><source><italic toggle="yes">International Journal of Pharmacy</italic></source><year>2007</year><volume>06</volume><issue>033</issue><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2007.06.033</pub-id><pub-id pub-id-type="pmid">17643877</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Racault</surname><given-names>C.</given-names></name><name name-style="western"><surname>Langlais</surname><given-names>F.</given-names></name><name name-style="western"><surname>Naslain</surname><given-names>R.</given-names></name></person-group><article-title>Solid-State Synthesis and Characterization of the Ternary Phase Ti3SiC2</article-title><source><italic toggle="yes">Journal of Materials Science</italic></source><year>1994</year><volume>29</volume><issue>13</issue><fpage>3384</fpage><lpage>3392</lpage><pub-id pub-id-type="doi">10.1007/BF00352037</pub-id><pub-id pub-id-type="other">2-s2.0-0028466632</pub-id></element-citation></ref><ref id="B60" content-type="article"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garanti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stasik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burrow</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Alhnan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>K.-W.</given-names></name></person-group><article-title>Anti-Glioma Activity and the Mechanism of Cellular Uptake of Asiatic Acid-Loaded Solid Lipid Nanoparticles</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2016</year><volume>500</volume><issue>1-2</issue><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.01.018</pub-id><pub-id pub-id-type="other">2-s2.0-84956872630</pub-id><pub-id pub-id-type="pmid">26775062</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Manjunath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhagawati</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Thippeswamy</surname><given-names>B. S.</given-names></name></person-group><article-title>Bixin Loaded Solid Lipid Nanoparticles for Enhanced Hepatoprotection&#8211;Preparation, Characterisation and In Vivo Evaluation</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2014</year><volume>473</volume><issue>1-2</issue><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.07.027</pub-id><pub-id pub-id-type="other">2-s2.0-84905492678</pub-id><pub-id pub-id-type="pmid">25066077</pub-id></element-citation></ref><ref id="B62" content-type="article"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jagadish</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced Ex Vivo Intestinal Absorption of Olmesartan Medoxomil Nanosuspension: Preparation by Combinative Technology</article-title><source><italic toggle="yes">Saudi Pharmaceutical Journal</italic></source><year>2016</year><volume>24</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2015.03.008</pub-id><pub-id pub-id-type="other">2-s2.0-84926144210</pub-id><pub-id pub-id-type="pmid">26903769</pub-id><pub-id pub-id-type="pmcid">PMC4720021</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles Loading Candesartan Cilexetil Enhance Oral Bioavailability: In Vitro Characteristics and Absorption Mechanism in Rats</article-title><source><italic toggle="yes">Nanomedicine: Nanotechnology, Biology and Medicine</italic></source><year>2012</year><volume>8</volume><issue>5</issue><fpage>740</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2011.08.016</pub-id><pub-id pub-id-type="other">2-s2.0-84862687247</pub-id><pub-id pub-id-type="pmid">21930110</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandya</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Jani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vanza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tandel</surname><given-names>H.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles as an Efficient Drug Delivery System of Olmesartan Medoxomil for the Treatment of Hypertension</article-title><source><italic toggle="yes">Colloids and Surfaces B: Biointerfaces</italic></source><year>2018</year><volume>165</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.02.011</pub-id><pub-id pub-id-type="other">2-s2.0-85041891775</pub-id><pub-id pub-id-type="pmid">29453084</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhalekar</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Madgulkar</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Desale</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Marium</surname><given-names>G.</given-names></name></person-group><article-title>Formulation of Piperine Solid Lipid Nanoparticles (SLN) for Treatment of Rheumatoid Arthritis</article-title><source><italic toggle="yes">Drug Development and Industrial Pharmacy</italic></source><year>2017</year><volume>43</volume><issue>6</issue><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1080/03639045.2017.1291666</pub-id><pub-id pub-id-type="other">2-s2.0-85014443968</pub-id><pub-id pub-id-type="pmid">28161984</pub-id></element-citation></ref><ref id="B66" content-type="article"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanna</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caria</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>A.</given-names></name></person-group><article-title>Effect of Lipid Nanoparticles Containing Fatty Alcohols Having Different Chain Length on the Ex Vivo Skin Permeability of Econazole Nitrate</article-title><source><italic toggle="yes">Powder Technology</italic></source><year>2010</year><volume>201</volume><issue>1</issue><fpage>32</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.powtec.2010.02.035</pub-id><pub-id pub-id-type="other">2-s2.0-77952290634</pub-id></element-citation></ref><ref id="B67" content-type="article"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>PLGA Nanoparticles Simultaneously Loaded With Vincristine Sulfate and Verapamil Hydrochloride: Systematic Study of Particle Size and Drug Entrapment Efficiency</article-title><source><italic toggle="yes">International Journal of Pharmaceutics</italic></source><year>2008</year><volume>350</volume><issue>1-2</issue><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.08.034</pub-id><pub-id pub-id-type="other">2-s2.0-38549178381</pub-id><pub-id pub-id-type="pmid">17913411</pub-id></element-citation></ref><ref id="B68" content-type="article"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yasir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A. P.</given-names></name></person-group><article-title>Glyceryl Monostearate Based Nanoparticles of Mefenamic Acid: Fabrication and In Vitro Characterization</article-title><source><italic toggle="yes">Drug Invention Today</italic></source><year>2013</year><volume>5</volume><issue>3</issue><fpage>246</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.dit.2013.06.011</pub-id><pub-id pub-id-type="other">2-s2.0-84884413538</pub-id></element-citation></ref><ref id="B69" content-type="article"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandagal</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Manjunatha</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Seetharamappa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalanur</surname><given-names>S. S.</given-names></name></person-group><article-title>RP&#8208;HPLC Method for the Determination of Tenofovir in Pharmaceutical Formulations and Spiked Human Plasma</article-title><source><italic toggle="yes">Analytical Letters</italic></source><year>2008</year><volume>41</volume><issue>4</issue><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1080/00032710801910742</pub-id><pub-id pub-id-type="other">2-s2.0-41549162973</pub-id></element-citation></ref><ref id="B70" content-type="article"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chokshi</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M. M.</given-names></name></person-group><article-title>Formulation, Optimization and Characterization of Rifampicin Loaded Solid Lipid Nanoparticles for the Treatment of Tuberculosis</article-title><source><italic toggle="yes">Drug Development and Industrial Pharmacy</italic></source><year>2018</year><volume>44</volume><issue>12</issue><fpage>1975</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.1080/03639045.2018.1506472</pub-id><pub-id pub-id-type="other">2-s2.0-85053043165</pub-id><pub-id pub-id-type="pmid">30058392</pub-id></element-citation></ref><ref id="B71" content-type="article"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelwahed</surname><given-names>W.</given-names></name><name name-style="western"><surname>Degobert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fessi</surname><given-names>H.</given-names></name></person-group><article-title>Investigation of Nanocapsules Stabilization by Amorphous Excipients During Freeze-Drying and Storage</article-title><source><italic toggle="yes">European Journal of Pharmaceutics and Biopharmaceutics</italic></source><year>2006</year><volume>63</volume><issue>2</issue><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2006.01.015</pub-id><pub-id pub-id-type="other">2-s2.0-33646830139</pub-id><pub-id pub-id-type="pmid">16621490</pub-id></element-citation></ref><ref id="B72" content-type="article"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estella-Hermoso de Mendoza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rayo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mollinedo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blanco-Prieto</surname><given-names>M. J.</given-names></name></person-group><article-title>Lipid Nanoparticles for Alkyl Lysophospholipidedelfosine Encapsulation: Development and In Vitro Characterization</article-title><source><italic toggle="yes">European Journal of Pharmaceutics and Biopharmaceutics</italic></source><year>2008</year><volume>68</volume><issue>2</issue><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2007.06.015</pub-id><pub-id pub-id-type="other">2-s2.0-37849010813</pub-id><pub-id pub-id-type="pmid">17707618</pub-id></element-citation></ref><ref id="B73" content-type="article"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madni</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Compritol-Based Alprazolam Solid Lipid Nanoparticles for Sustained Release of Alprazolam: Preparation by Hot Melt Encapsulation</article-title><source><italic toggle="yes">Molecules</italic></source><year>2022</year><volume>27</volume><issue>24</issue><fpage>p. 8894</fpage><pub-id pub-id-type="doi">10.3390/molecules27248894</pub-id><pub-id pub-id-type="pmcid">PMC9783086</pub-id><pub-id pub-id-type="pmid">36558027</pub-id></element-citation></ref><ref id="B74" content-type="article"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sunil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harish</surname><given-names>D.</given-names></name></person-group><article-title>Structural Composition of Solid Lipid Nanoparticles for Invasive and Noninvasive Drug Delivery</article-title><source><italic toggle="yes">Current Nanomaterials</italic></source><year>2017</year><volume>2</volume><issue>3</issue><fpage>129</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.2174/2405461503666180413160954</pub-id></element-citation></ref><ref id="B75" content-type="article"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawar</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meher</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chourasia</surname><given-names>M. K.</given-names></name></person-group><article-title>Engineered Nanocrystal Technology: In-Vivo Fate, Targeting and Applications in Drug Delivery</article-title><source><italic toggle="yes">Journal of Controlled Release</italic></source><year>2014</year><volume>183</volume><fpage>51</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.03.030</pub-id><pub-id pub-id-type="other">2-s2.0-84898032532</pub-id><pub-id pub-id-type="pmid">24667572</pub-id></element-citation></ref><ref id="B76" content-type="article"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirchandani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Patravale</surname><given-names>V. B.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles for Hydrophilic Drugs</article-title><source><italic toggle="yes">Journal of Controlled Release</italic></source><year>2021</year><volume>335</volume><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.05.032</pub-id><pub-id pub-id-type="pmid">34048841</pub-id></element-citation></ref><ref id="B77" content-type="article"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subroto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andoyo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Indiarto</surname><given-names>R.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles: Review of the Current Research on Encapsulation and Delivery Systems for Active and Antioxidant Compounds</article-title><source><italic toggle="yes">Antioxidants</italic></source><year>2023</year><volume>12</volume><issue>3</issue><fpage>p. 633</fpage><pub-id pub-id-type="doi">10.3390/antiox12030633</pub-id><pub-id pub-id-type="pmcid">PMC10045442</pub-id><pub-id pub-id-type="pmid">36978881</pub-id></element-citation></ref><ref id="B78" content-type="article"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khaja Mohinuddin Salar</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>N.</given-names></name><name name-style="western"><surname>David</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>V. D.</given-names></name></person-group><article-title>Impact of Organic Solvents and Environmental Pollutants on the Physiological Function in Petrol Filling Workers</article-title><source><italic toggle="yes">International Journal of Environmental Research and Public Health</italic></source><year>2008</year><volume>5</volume><issue>3</issue><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.3390/ijerph5030139</pub-id><pub-id pub-id-type="other">2-s2.0-54349090583</pub-id><pub-id pub-id-type="pmid">19139531</pub-id><pub-id pub-id-type="pmcid">PMC3699983</pub-id></element-citation></ref><ref id="B79" content-type="article"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mudassir</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mohtar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Darwis</surname><given-names>Y.</given-names></name></person-group><article-title>Advanced Drug Delivery to the Lymphatic System: Lipid-Based Nanoformulations</article-title><source><italic toggle="yes">International Journal of Nanomedicine</italic></source><year>2013</year><volume>8</volume><fpage>2733</fpage><lpage>2744</lpage><pub-id pub-id-type="doi">10.2147/IJN.S41521</pub-id><pub-id pub-id-type="other">2-s2.0-84880774809</pub-id><pub-id pub-id-type="pmid">23926431</pub-id><pub-id pub-id-type="pmcid">PMC3732201</pub-id></element-citation></ref><ref id="B80" content-type="article"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name></person-group><article-title>Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy</article-title><source><italic toggle="yes">Nano-Micro Letters</italic></source><year>2023</year><volume>15</volume><issue>1</issue><fpage>p. 145</fpage><pub-id pub-id-type="doi">10.1007/s40820-023-01125-2</pub-id><pub-id pub-id-type="pmcid">PMC10239433</pub-id><pub-id pub-id-type="pmid">37269391</pub-id></element-citation></ref><ref id="B81" content-type="article"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yassin</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Anwer</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Mowafy</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>El-Bagory</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Bayomi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Alsarra</surname><given-names>I. A.</given-names></name></person-group><article-title>Optimization of 5-Flurouracil Solid-Lipid Nanoparticles: A Preliminary Study to Treat Colon Cancer</article-title><source><italic toggle="yes">International Journal of Medical Sciences</italic></source><year>2010</year><volume>7</volume><issue>6</issue><fpage>398</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.7150/ijms.7.398</pub-id><pub-id pub-id-type="other">2-s2.0-78649671277</pub-id><pub-id pub-id-type="pmid">21103076</pub-id><pub-id pub-id-type="pmcid">PMC2990076</pub-id></element-citation></ref><ref id="B82" content-type="article"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekambaram</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abdul</surname><given-names>H. S.</given-names></name></person-group><article-title>Formulation and Evaluation of Solid Lipid Nanoparticles of Ramipril</article-title><source><italic toggle="yes">Journal of Young Pharmacists</italic></source><year>2011</year><volume>3</volume><issue>3</issue><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.4103/0975-1483.83765</pub-id><pub-id pub-id-type="other">2-s2.0-80051869434</pub-id><pub-id pub-id-type="pmid">21897661</pub-id><pub-id pub-id-type="pmcid">PMC3159275</pub-id></element-citation></ref><ref id="B83" content-type="article"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qushawy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prabahar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abd-Alhaseeb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swidan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>A.</given-names></name></person-group><article-title>Preparation and Evaluation of Carbamazepine Solid Lipid Nanoparticle for Alleviating Seizure Activity in Pentylenetetrazole-Kindled Mice</article-title><source><italic toggle="yes">Molecules</italic></source><year>2019</year><volume>24</volume><issue>21</issue><fpage>p. 3971</fpage><pub-id pub-id-type="doi">10.3390/molecules24213971</pub-id><pub-id pub-id-type="pmid">31684021</pub-id><pub-id pub-id-type="pmcid">PMC6864770</pub-id></element-citation></ref><ref id="B84" content-type="article"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Preeti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S. S.</given-names></name></person-group><article-title>Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate</article-title><source><italic toggle="yes">Current Drug Delivery</italic></source><year>2018</year><volume>15</volume><issue>6</issue><fpage>818</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.2174/1567201814666170525121049</pub-id><pub-id pub-id-type="other">2-s2.0-85046604591</pub-id><pub-id pub-id-type="pmid">28545354</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Ishikawa/fishbone diagram for risk assessment in development of TNF-loaded SLNs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Screening of lipid, surfactant, and formulation technique (B wax&#8201;=&#8201;beeswax, Chole&#8201;=&#8201;cholesterol, Comp&#8201;=&#8201;Compritol 888 ATO, CP&#8201;=&#8201;cetyl palmitate, GMS&#8201;=&#8201;glyceryl monostearate, GPS&#8201;=&#8201;glyceryl palmitostearate, HPH&#8201;=&#8201;high-pressure homogenization, ME&#8201;=&#8201;microemulsion, SA&#8201;=&#8201;stearic acid, S. al&#8201;=&#8201;stearyl alcohol, and SE&#8201;=&#8201;solvent evaporation).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.002.jpg"/></fig><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>FTIR spectral analysis: (a) IR spectra of drug (tenofovir) and (b) IR spectra of physical mixture (drug (tenofovir)&#8201;+&#8201;lipid (Compritol 888 ATO)&#8201;+&#8201;surfactant (poloxamer 188).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.003.jpg"/></fig><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Contour and 3D surface graphs: (a&#8211;c) contour plots; (d&#8211;f) 3D surface graphs demonstrating the impact of independent parameters on Response I (particle size) and Response II (% entrapment efficiency); (g&#8211;i) overlay plots for optimization of TNF-loaded SLNs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.004.jpg"/></fig><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Comparing in vitro release and ex vivo permeation profiles of optimized SLNs formulation (TF10) with pure drug solution.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.005.jpg"/></fig><fig position="float" id="fig6" orientation="portrait"><label>Figure 6</label><caption><p>Differential scanning calorimetry graphs. (a) Pure drug tenofovir; (b) physical mixture of TNF&#8201;+&#8201;excipients; (c) optimized TNF-loaded SLN formulation (TF10).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.006.jpg"/></fig><fig position="float" id="fig7" orientation="portrait"><label>Figure 7</label><caption><p>X-ray diffraction graphs. (a) Pure drug tenofovir; (b) physical mixture of TNF&#8201;+&#8201;excipients; (c) optimized TNF-loaded SLN formulation (TF10).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.007.jpg"/></fig><fig position="float" id="fig8" orientation="portrait"><label>Figure 8</label><caption><p>Scanning electron micrographs of optimized TNF-loaded SLN formulation (TF10).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.008.jpg"/></fig><fig position="float" id="fig9" orientation="portrait"><label>Figure 9</label><caption><p>Tenofovir's plasma concentration vs time profile following oral administration of TNF-loaded SLNs and pure TNF solution (10&#8201;mg/kg).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="APS2024-5248746.009.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Components of quality target product profile (QTPP) and critical quality attributes (CQAs) for optimizing tenofovir-loaded solid lipid nanoparticles (TNF-loaded SLNs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#8201;</th><th align="center" rowspan="1" colspan="1">Target</th><th align="center" rowspan="1" colspan="1">Justification</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Quality target product profile (QTPPs)</italic>
</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug delivery system</td><td align="center" rowspan="1" colspan="1">Solid lipid nanoparticles</td><td align="center" rowspan="1" colspan="1">Promotes oral bioavailability and greater brain uptake</td></tr><tr><td align="left" rowspan="1" colspan="1">Dosage type</td><td align="center" rowspan="1" colspan="1">Controlled release</td><td align="center" rowspan="1" colspan="1">Prolonged drug therapy is achieved</td></tr><tr><td align="left" rowspan="1" colspan="1">Route of administration</td><td align="center" rowspan="1" colspan="1">Oral</td><td align="center" rowspan="1" colspan="1">Patient compliance</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug release</td><td align="center" rowspan="1" colspan="1">More than 80%</td><td align="center" rowspan="1" colspan="1">Necessary for the best possible treatment outcome</td></tr><tr><td align="left" colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Critical quality attributes (CQAs)</italic>
</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">Particle size</td><td align="center" rowspan="1" colspan="1">Less than 200&#8201;nm</td><td align="center" rowspan="1" colspan="1">Offers lymphatic uptake and escapes reticular endothelial system (RES)</td></tr><tr><td align="left" rowspan="1" colspan="1">Entrapment efficiency</td><td align="center" rowspan="1" colspan="1">More than 80%</td><td align="center" rowspan="1" colspan="1">Enhanced pharmacological and therapeutic action</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Experimental runs and coded values for optimizing TNF-loaded SLNs using the Box&#8211;Behnken design.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">No. of runs</th><th align="center" rowspan="1" colspan="1">Formulation code</th><th align="center" rowspan="1" colspan="1">Factor 1 (A: lipid, %w/v)</th><th align="center" rowspan="1" colspan="1">Factor 2 (B: surfactant, %w/v)</th><th align="center" rowspan="1" colspan="1">Factor 3 (C: homogenization time, min)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">TF1</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">TF2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">TF3</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">TF4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">TF5</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">TF6</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">TF7</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">TF8</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">TF9</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">TF10</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">TF11</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">TF12</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">TF13</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">90</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Resulting data from mean particle size, PDI, zeta potential, and % entrapment efficiency analysis of TNF-loaded SLNs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Formulation code</th><th align="center" rowspan="1" colspan="1">Particle size (Response 1) (nm)</th><th align="center" rowspan="1" colspan="1">PDI</th><th align="center" rowspan="1" colspan="1">Zeta potential (mV)</th><th align="center" rowspan="1" colspan="1">Entrapment efficiency (Response 2) (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TF1</td><td align="center" rowspan="1" colspan="1">573.31&#8201;&#177;&#8201;2.34</td><td align="center" rowspan="1" colspan="1">0.580&#8201;&#177;&#8201;0.163</td><td align="center" rowspan="1" colspan="1">&#8722;17.72&#8201;&#177;&#8201;2.34</td><td align="center" rowspan="1" colspan="1">58.16&#8201;&#177;&#8201;4.22</td></tr><tr><td align="left" rowspan="1" colspan="1">TF2</td><td align="center" rowspan="1" colspan="1">99.92&#8201;&#177;&#8201;4.23</td><td align="center" rowspan="1" colspan="1">0.498&#8201;&#177;&#8201;0.176</td><td align="center" rowspan="1" colspan="1">&#8722;10.32&#8201;&#177;&#8201;3.91</td><td align="center" rowspan="1" colspan="1">34.67&#8201;&#177;&#8201;2.07</td></tr><tr><td align="left" rowspan="1" colspan="1">TF3</td><td align="center" rowspan="1" colspan="1">993.84&#8201;&#177;&#8201;4.56</td><td align="center" rowspan="1" colspan="1">0.527&#8201;&#177;&#8201;0.008</td><td align="center" rowspan="1" colspan="1">&#8722;21.43&#8201;&#177;&#8201;2.34</td><td align="center" rowspan="1" colspan="1">76.54&#8201;&#177;&#8201;3.12</td></tr><tr><td align="left" rowspan="1" colspan="1">TF4</td><td align="center" rowspan="1" colspan="1">86.71&#8201;&#177;&#8201;6.45</td><td align="center" rowspan="1" colspan="1">0.151&#8201;&#177;&#8201;0.058</td><td align="center" rowspan="1" colspan="1">&#8722;8.78&#8201;&#177;&#8201;2.38</td><td align="center" rowspan="1" colspan="1">40.05&#8201;&#177;&#8201;4.98</td></tr><tr><td align="left" rowspan="1" colspan="1">TF5</td><td align="center" rowspan="1" colspan="1">520.23&#8201;&#177;&#8201;2.87</td><td align="center" rowspan="1" colspan="1">0.563&#8201;&#177;&#8201;0.154</td><td align="center" rowspan="1" colspan="1">&#8722;14.19&#8201;&#177;&#8201;1.48</td><td align="center" rowspan="1" colspan="1">66.14&#8201;&#177;&#8201;1.82</td></tr><tr><td align="left" rowspan="1" colspan="1">TF6</td><td align="center" rowspan="1" colspan="1">550.57&#8201;&#177;&#8201;3.58</td><td align="center" rowspan="1" colspan="1">0.346&#8201;&#177;&#8201;0.47</td><td align="center" rowspan="1" colspan="1">&#8722;16.90&#8201;&#177;&#8201;3.27</td><td align="center" rowspan="1" colspan="1">75.34&#8201;&#177;&#8201;3.07</td></tr><tr><td align="left" rowspan="1" colspan="1">TF7</td><td align="center" rowspan="1" colspan="1">720.12&#8201;&#177;&#8201;4.89</td><td align="center" rowspan="1" colspan="1">0.393&#8201;&#177;&#8201;0.42</td><td align="center" rowspan="1" colspan="1">&#8722;22.68&#8201;&#177;&#8201;2.98</td><td align="center" rowspan="1" colspan="1">81.02&#8201;&#177;&#8201;4.12</td></tr><tr><td align="left" rowspan="1" colspan="1">TF8</td><td align="center" rowspan="1" colspan="1">801.40&#8201;&#177;&#8201;1.34</td><td align="center" rowspan="1" colspan="1">0.503&#8201;&#177;&#8201;0.006</td><td align="center" rowspan="1" colspan="1">&#8722;24.09&#8201;&#177;&#8201;1.19</td><td align="center" rowspan="1" colspan="1">76.10&#8201;&#177;&#8201;6.06</td></tr><tr><td align="left" rowspan="1" colspan="1">TF9</td><td align="center" rowspan="1" colspan="1">96.80&#8201;&#177;&#8201;2.67</td><td align="center" rowspan="1" colspan="1">0.298&#8201;&#177;&#8201;0.005</td><td align="center" rowspan="1" colspan="1">&#8722;7.45&#8201;&#177;&#8201;3.67</td><td align="center" rowspan="1" colspan="1">40.89&#8201;&#177;&#8201;5.19</td></tr><tr><td align="left" rowspan="1" colspan="1">TF10</td><td align="center" rowspan="1" colspan="1">449.90&#8201;&#177;&#8201;4.79</td><td align="center" rowspan="1" colspan="1">0.304&#8201;&#177;&#8201;0.004</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">83.13&#8201;&#177;&#8201;6.34</td></tr><tr><td align="left" rowspan="1" colspan="1">TF11</td><td align="center" rowspan="1" colspan="1">506.51&#8201;&#177;&#8201;5.94</td><td align="center" rowspan="1" colspan="1">0.314&#8201;&#177;&#8201;0.004</td><td align="center" rowspan="1" colspan="1">&#8722;13.70&#8201;&#177;&#8201;2.92</td><td align="center" rowspan="1" colspan="1">72.76&#8201;&#177;&#8201;3.29</td></tr><tr><td align="left" rowspan="1" colspan="1">TF12</td><td align="center" rowspan="1" colspan="1">79.09&#8201;&#177;&#8201;3.97</td><td align="center" rowspan="1" colspan="1">0.271&#8201;&#177;&#8201;0.012</td><td align="center" rowspan="1" colspan="1">&#8722;5.74&#8201;&#177;&#8201;3.56</td><td align="center" rowspan="1" colspan="1">24.78&#8201;&#177;&#8201;4.52</td></tr><tr><td align="left" rowspan="1" colspan="1">TF13</td><td align="center" rowspan="1" colspan="1">732.50&#8201;&#177;&#8201;2.65</td><td align="center" rowspan="1" colspan="1">0.549&#8201;&#177;&#8201;0.123</td><td align="center" rowspan="1" colspan="1">&#8722;23.02&#8201;&#177;&#8201;1.14</td><td align="center" rowspan="1" colspan="1">68.45&#8201;&#177;&#8201;4.86</td></tr></tbody></table></table-wrap><table-wrap-group position="float" id="tab4" orientation="portrait"><label>Table 4</label><caption><p>(a) Response I (particle size) ANOVA using response surface quadratic model. (b) Response II (% entrapment efficiency) ANOVA using response surface quadratic model.</p></caption><table-wrap position="anchor" id="tab4a" orientation="portrait"><label>(a)</label><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Source</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Sum of squares</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>df</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Mean square</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">F</italic> value</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>p</bold>
<bold>value</bold>
</td><td align="center" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Model</td><td align="center" rowspan="1" colspan="1">1.087<italic toggle="yes">E</italic>&#8201;+&#8201;06</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.208<italic toggle="yes">E</italic>&#8201;+&#8201;05</td><td align="center" rowspan="1" colspan="1">14.58</td><td align="center" rowspan="1" colspan="1">0.0247</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#8212;lipid concentration</td><td align="center" rowspan="1" colspan="1">1.041<italic toggle="yes">E</italic>&#8201;+&#8201;06</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.041<italic toggle="yes">E</italic>&#8201;+&#8201;06</td><td align="center" rowspan="1" colspan="1">125.57</td><td align="center" rowspan="1" colspan="1">0.0015</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#8212;surfactant concentration</td><td align="center" rowspan="1" colspan="1">750.78</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">750.78</td><td align="center" rowspan="1" colspan="1">0.0906</td><td align="center" rowspan="1" colspan="1">0.0310</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">C&#8212;homogenization time</td><td align="center" rowspan="1" colspan="1">483.60</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">483.60</td><td align="center" rowspan="1" colspan="1">0.0584</td><td align="center" rowspan="1" colspan="1">0.0247</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">AB</td><td align="center" rowspan="1" colspan="1">11,046.01</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">11,046.01</td><td align="center" rowspan="1" colspan="1">1.33</td><td align="center" rowspan="1" colspan="1">0.3319</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">AC</td><td align="center" rowspan="1" colspan="1">0.1225</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.1225</td><td align="center" rowspan="1" colspan="1">0.0000</td><td align="center" rowspan="1" colspan="1">0.9972</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">BC</td><td align="center" rowspan="1" colspan="1">20.70</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">20.70</td><td align="center" rowspan="1" colspan="1">0.0025</td><td align="center" rowspan="1" colspan="1">0.9633</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">A</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">4128.57</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4128.57</td><td align="center" rowspan="1" colspan="1">0.4982</td><td align="center" rowspan="1" colspan="1">0.5312</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">B</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">16,650.57</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">16,650.57</td><td align="center" rowspan="1" colspan="1">2.01</td><td align="center" rowspan="1" colspan="1">0.2514</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">12.89</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">12.89</td><td align="center" rowspan="1" colspan="1">0.0016</td><td align="center" rowspan="1" colspan="1">0.9710</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Residual</td><td align="center" rowspan="1" colspan="1">24,862.47</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">8287.49</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cor total</td><td align="center" rowspan="1" colspan="1">1.112<italic toggle="yes">E</italic>&#8201;+&#8201;06</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="tab4b" orientation="portrait"><label>(b)</label><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Source</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Sum of squares</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>df</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Mean square</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">F</italic> value</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>p</bold>
<bold>value</bold>
</td><td align="center" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Model</td><td align="center" rowspan="1" colspan="1">5154.04</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">572.67</td><td align="center" rowspan="1" colspan="1">86.91</td><td align="center" rowspan="1" colspan="1">0.0018</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#8212;lipid concentration</td><td align="center" rowspan="1" colspan="1">3836.44</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3836.44</td><td align="center" rowspan="1" colspan="1">582.26</td><td align="center" rowspan="1" colspan="1">0.0002</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#8212;surfactant concentration</td><td align="center" rowspan="1" colspan="1">115.82</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">115.82</td><td align="center" rowspan="1" colspan="1">17.58</td><td align="center" rowspan="1" colspan="1">0.0247</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">C&#8212;homogenization time</td><td align="center" rowspan="1" colspan="1">185.19</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">185.19</td><td align="center" rowspan="1" colspan="1">28.11</td><td align="center" rowspan="1" colspan="1">0.0131</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">AB</td><td align="center" rowspan="1" colspan="1">179.83</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">179.83</td><td align="center" rowspan="1" colspan="1">27.29</td><td align="center" rowspan="1" colspan="1">0.0136</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">AC</td><td align="center" rowspan="1" colspan="1">6.13</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6.13</td><td align="center" rowspan="1" colspan="1">0.9297</td><td align="center" rowspan="1" colspan="1">0.4061</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">BC</td><td align="center" rowspan="1" colspan="1">7.56</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.56</td><td align="center" rowspan="1" colspan="1">1.15</td><td align="center" rowspan="1" colspan="1">0.3625</td><td align="center" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">A</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">806.90</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">806.90</td><td align="center" rowspan="1" colspan="1">122.46</td><td align="center" rowspan="1" colspan="1">0.0016</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">B</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">92.78</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">92.78</td><td align="center" rowspan="1" colspan="1">14.08</td><td align="center" rowspan="1" colspan="1">0.0331</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">79.80</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">79.80</td><td align="center" rowspan="1" colspan="1">12.11</td><td align="center" rowspan="1" colspan="1">0.0401</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Residual</td><td align="center" rowspan="1" colspan="1">19.77</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.59</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cor total</td><td align="center" rowspan="1" colspan="1">5173.81</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap position="float" id="tab5" orientation="portrait"><label>Table 5</label><caption><p>Summary of Box&#8211;Behnken design's ANOVA results for TNF-loaded SLN optimization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">S. no.</th><th align="center" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Response I (particle size)</th><th align="center" rowspan="1" colspan="1">Response II (% entrapment efficiency)</th><th align="center" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">F</italic> value</td><td align="center" rowspan="1" colspan="1">14.58</td><td align="center" rowspan="1" colspan="1">86.91</td><td align="center" rowspan="1" colspan="1">Model terms were significant</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</td><td align="center" rowspan="1" colspan="1">0.0247</td><td align="center" rowspan="1" colspan="1">0.0018</td><td align="center" rowspan="1" colspan="1">Model terms were significant</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup> value</td><td align="center" rowspan="1" colspan="1">0.9106</td><td align="center" rowspan="1" colspan="1">0.9847</td><td align="center" rowspan="1" colspan="1">Response parameters and formulation variables exhibit good agreement</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab6" orientation="portrait"><label>Table 6</label><caption><p>Pharmacokinetic data of pure TNF solution and optimized TNF-loaded SLNs (TF10), mean&#8201;&#177;&#8201;SD (n&#8201;=&#8201;6).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Pure TNF solution</th><th align="center" rowspan="1" colspan="1">Opt. TNF-loaded SLNs (F7)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>
</td><td align="center" rowspan="1" colspan="1">226&#8201;&#177;&#8201;510.56&#8201;ng/mL</td><td align="center" rowspan="1" colspan="1">781&#8201;&#177;&#8201;4.12&#8201;ng/mL</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub>
</td><td align="center" rowspan="1" colspan="1">0.5&#8201;h&#8201;&#177;&#8201;0.01</td><td align="center" rowspan="1" colspan="1">3&#8201;h&#8201;&#177;&#8201;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">a</italic>
</sub>
</td><td align="center" rowspan="1" colspan="1">0.43&#8201;&#177;&#8201;0.27&#8201;h<sup>&#8722;1</sup></td><td align="center" rowspan="1" colspan="1">3.59&#8201;&#177;&#8201;2.17&#8201;h<sup>&#8722;1</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">E</italic>
</sub>
</td><td align="center" rowspan="1" colspan="1">1.18&#8201;&#177;&#8201;0.49&#8201;h<sup>&#8722;1</sup></td><td align="center" rowspan="1" colspan="1">0.57&#8201;&#177;&#8201;0.22&#8201;h<sup>&#8722;1</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub>
</td><td align="center" rowspan="1" colspan="1">10.6&#8201;&#177;&#8201;2.02&#8201;h</td><td align="center" rowspan="1" colspan="1">18.61&#8201;&#177;&#8201;0.35&#8201;h</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0&#8722;24</sub></td><td align="center" rowspan="1" colspan="1">1237&#8201;&#177;&#8201;52.41&#8201;ng/h mL<sup>&#8722;1</sup></td><td align="center" rowspan="1" colspan="1">15,338&#8201;&#177;&#8201;22.30&#8201;ng/h mL<sup>&#8722;1</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">[AUC]<sub>0&#8722;<italic toggle="yes">&#8734;</italic></sub></td><td align="center" rowspan="1" colspan="1">1049.28&#8201;&#177;&#8201;155.16&#8201;ng/h mL<sup>&#8722;1</sup></td><td align="center" rowspan="1" colspan="1">29,083.16&#8201;&#177;&#8201;118.36&#8201;ng/hr mL<sup>&#8722;1</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MRT</td><td align="center" rowspan="1" colspan="1">16.28&#8201;&#177;&#8201;3.68&#8201;h</td><td align="center" rowspan="1" colspan="1">36.12&#8201;&#177;&#8201;2.12&#8201;h</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab7" orientation="portrait"><label>Table 7</label><caption><p>Stability study data of optimized TNF-loaded SLN (TF10) formulation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Stability testing condition</th><th align="center" rowspan="2" colspan="1">Parameters</th><th align="center" colspan="4" rowspan="1">Sampling intervals</th></tr><tr><th align="center" rowspan="1" colspan="1">0 days</th><th align="center" rowspan="1" colspan="1">30&#8201;days</th><th align="center" rowspan="1" colspan="1">60&#8201;days</th><th align="center" rowspan="1" colspan="1">90&#8201;days</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">2&#8211;8&#176;C</td><td align="center" rowspan="1" colspan="1">Particle size</td><td align="center" rowspan="1" colspan="1">449.90&#8201;&#177;&#8201;4.79</td><td align="center" rowspan="1" colspan="1">449.16&#8201;&#177;&#8201;5.04</td><td align="center" rowspan="1" colspan="1">449.78&#8201;&#177;&#8201;5.18</td><td align="center" rowspan="1" colspan="1">450.16&#8201;&#177;&#8201;5.04</td></tr><tr><td align="center" rowspan="1" colspan="1">%EE</td><td align="center" rowspan="1" colspan="1">81.55&#8201;&#177;&#8201;1.74</td><td align="center" rowspan="1" colspan="1">81.53&#8201;&#177;&#8201;1.23</td><td align="center" rowspan="1" colspan="1">81.43&#8201;&#177;&#8201;1.57</td><td align="center" rowspan="1" colspan="1">81.32&#8201;&#177;&#8201;1.65</td></tr><tr><td align="center" rowspan="1" colspan="1">Zeta potential</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;3.25</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">25&#8201;&#177;&#8201;2&#176;C/65&#8201;&#177;&#8201;5%RH</td><td align="center" rowspan="1" colspan="1">Particle size</td><td align="center" rowspan="1" colspan="1">449.90&#8201;&#177;&#8201;4.79</td><td align="center" rowspan="1" colspan="1">449.97&#8201;&#177;&#8201;5.12</td><td align="center" rowspan="1" colspan="1">449.97&#8201;&#177;&#8201;6.09</td><td align="center" rowspan="1" colspan="1">452.17&#8201;&#177;&#8201;2.09</td></tr><tr><td align="center" rowspan="1" colspan="1">%EE</td><td align="center" rowspan="1" colspan="1">81.55&#8201;&#177;&#8201;1.74</td><td align="center" rowspan="1" colspan="1">81.47&#8201;&#177;&#8201;1.06</td><td align="center" rowspan="1" colspan="1">81.36&#8201;&#177;&#8201;1.53</td><td align="center" rowspan="1" colspan="1">80.97&#8201;&#177;&#8201;1.04</td></tr><tr><td align="center" rowspan="1" colspan="1">Zeta potential</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">&#8722;18.02&#8201;&#177;&#8201;2.54</td><td align="center" rowspan="1" colspan="1">&#8722;18.02&#8201;&#177;&#8201;3.07</td><td align="center" rowspan="1" colspan="1">&#8722;18.02&#8201;&#177;&#8201;3.07</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">40&#8201;&#177;&#8201;2&#176;C/75&#8201;&#177;&#8201;5%RH</td><td align="center" rowspan="1" colspan="1">Particle size</td><td align="center" rowspan="1" colspan="1">449.90&#8201;&#177;&#8201;4.79</td><td align="center" rowspan="1" colspan="1">451.54&#8201;&#177;&#8201;5.03</td><td align="center" rowspan="1" colspan="1">451.54&#8201;&#177;&#8201;7.34</td><td align="center" rowspan="1" colspan="1">455.54&#8201;&#177;&#8201;3.17</td></tr><tr><td align="center" rowspan="1" colspan="1">%EE</td><td align="center" rowspan="1" colspan="1">81.55&#8201;&#177;&#8201;1.74</td><td align="center" rowspan="1" colspan="1">81.37&#8201;&#177;&#8201;2.06</td><td align="center" rowspan="1" colspan="1">81.03&#8201;&#177;&#8201;3.19</td><td align="center" rowspan="1" colspan="1">80.03&#8201;&#177;&#8201;4.01</td></tr><tr><td align="center" rowspan="1" colspan="1">Zeta potential</td><td align="center" rowspan="1" colspan="1">&#8722;18.10&#8201;&#177;&#8201;2.35</td><td align="center" rowspan="1" colspan="1">&#8722;18.01&#8201;&#177;&#8201;3.51</td><td align="center" rowspan="1" colspan="1">&#8722;17.01&#8201;&#177;&#8201;2.15</td><td align="center" rowspan="1" colspan="1">&#8722;17.01&#8201;&#177;&#8201;1.15</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>